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ABSTRACT 
 Infectious diseases that spread from person-to-person and continent-to-continent are a 
cause for concern for any health entity.  One such disease is malaria, a mosquito-borne infection 
instigated by the protozoan parasite, Plasmodium falciparum.  Hundreds of millions of people 
are affected annually and it is responsible for nearly 1 million deaths.  It is the most fatal species 
causing malaria and proliferates in human red blood cells with a life cycle occurring every 48 
hours.  At this time, the parasite’s late stage form or schizont bursts from the erythrocyte 
releasing immune-inducing particles and infective forms (merozoites) into the bloodstream.  The 
merozoites go on to infect other red blood cells as human immunity leads to fever.  Fever is a 
hallmark symptom of malaria and effectively inhibits the growth of late stage parasites.  
Plasmodium still manages to complete its life cycle as early stages or rings are not affected by 
febrile temperatures.  It is this facet of parasite biology that prompts our research into identifying 
genetic factors associated with fever.    
The parasite’s response under elevated body temperature may offer further insight into its 
adaptive mechanism.  A heat shock assay was developed in order to simulate fever in vitro.  
Mutant parasite cultures were subjected to 41°C for 8 hours and returned to normal body 
temperature or 37°C for the remainder of the life cycle.  The piggyBac mutagenesis system 
allows for the evaluation of phenotypes associated with a particular genotype as the transposon 
inserts randomly into the gene.  This often leads to changes in function that may cause delays in 
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invasion or attenuation of growth.  Determining the genes responsible for these phenotypes 
would be a great advantage to the field of drug discovery.   
Collaborative efforts to develop vaccines and new antimalarial drugs are underway as 
resistance to current methods of treatment is on the rise.  Such circumstances require new 
technologies for detecting novel drug targets or pathways in the parasite that can be significantly 
affected by these therapeutics.  QISeq is a next generation sequencing tool that identifies genes 
with a particular phenotype that may alter intraerythrocytic development of P. falciparum.  This 
technique was utilized in our study to confirm the heat shock phenotype with a high-throughput 
approach.  The genomic DNA of pooled parasite cultures was sequenced to reveal those mutants 
sensitive and/or resistant to febrile temperature exposure.  Through bioinformatics analyses, 
functional associations between genes can be made that lead to biological pathways of interest 
for therapeutic research. 
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CHAPTER ONE:  
INTRODUCTION 
 
Background  
Malaria: Defining “Bad Air” 
Before modern medicine and technological advances established the etiology of a 
particular illness, many diseases were thought to be caused by humors or “something in the air.”  
Hence, the root of the word for malaria as translated in Italian to mean bad air.  We now know 
that malaria is caused by the bite of an infected Anopheles mosquito carrying parasites of the 
phylum Apicomplexa and genus Plasmodium.  It is not the air itself that transmits the infection, 
but tropical climates and standing water that allow for the propagation of these insect pests that 
do.  Once the protozoan parasites enter the human body from the female mosquito host, they 
cause a wide range of molecular and cellular changes.   
 
Geographic Distribution of Human Malarias 
At present, there are five species of malaria that infect humans, Plasmodium falciparum P. 
vivax, P. malariae, P. ovale, and P. knowlesi.  Malaria is a serious infectious disease and is 
responsible for nearly one million deaths and hundreds of millions of infections worldwide per 
year.  The World Health Organization estimates that of the 198 million cases of malaria in 2013, 
approximately 128 million infections are caused by P. falciparum, the deadliest form of the 
disease, in sub-Saharan Africa alone (Figure 1.1, [44]).  This global threat affects people in many 
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different regions of the world from the Americas, Africa, to the Mediterranean, Asia and so on, 
where the greatest risk of death is in children under five and pregnant women.  In the United 
States, sporadic outbreaks of malaria occur in Florida and Southern California and are caused by 
P. vivax as well as travelers from endemic countries.   
 
Life Cycle of Plasmodium  
Growth and development of protozoan parasites in the genus, Plasmodium, are quite 
complex.  There are typically two hosts involved in this process, the mosquito vector and a 
vertebrate animal (Figure 1.2, [9]).  The sexual cycle occurs in the mid-gut of the female 
Anopheles mosquito, where an infective form known as the sporozoite migrates to the salivary 
gland in preparation for a blood meal (12, 14).  This process begins with the uptake of male and 
female gametocytes from an infected human host.  According to Touray and others, fertilization 
occurs in the mosquito midgut, producing oökinetes that move through the midgut and develop 
into oocysts (43).  These oocysts divide and mature into sporozoites that move through the 
hemocoel toward the salivary glands after nearly nine days (14, 43).  Once the sporozoite is 
injected into the human host, it makes its way to the liver, undergoes differentiation (in the pre-
erythrocytic or intrahepatocytic cycle), and seeks out red blood cells to invade [12].   
From this point on, the asexual cycle has begun and the parasite uses up host cell 
nutrients, multiplies, and re-invades.  During the blood stage (which takes approximately 48 
hours to complete in the case of P. falciparum), the parasite starts as a ring-shaped object in the 
erythrocyte, then grows as a single nucleus-containing trophozoite, and ultimately differentiating 
into a multi-nucleated schizont before rupturing to release invasive merozoites (16).  These 
invading cells known as merozoites are released and attach themselves to waiting erythrocytes, a 
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mechanism that has been well-studied.  Within the merozoite are apical organelles, specific to 
apicomplexan parasites, such as micronemes, rhoptries, and dense granules that are responsible 
for invasion.  Once in contact with the red blood cell surface, the merozoite reorients itself such 
that its apex is joined to the erythrocyte membrane (13).  This causes invagination of the red 
blood cell, allowing the merozoite to invade and elude detection by the host’s immune system.   
Invasion is largely facilitated by a tight junction that forms between the parasite and the 
erythrocyte.  Since the P. falciparum genome and transcriptome were published, information on 
the genes and proteins involved in this process has been revealed.  Upon entry, the outer coat of 
the merozoite is removed by proteases that also detach ligands responsible for further traversal of 
the parasite into the host cell while forming a parasitophorous vacuole (12).  The Plasmodium 
parasite contains surface proteins and ligands that bind to receptors on red blood cells deemed 
suitable for invasion.  The micronemal protein known as the erythrocyte binding antigen-175 
(EBA-175) is part of the Duffy binding-like family of proteins that facilitates invasion through 
binding of the glycophorin A receptor on the erythrocyte in the presence of sialic acid (17, 25).  
Another protein that mediates invasion is one involved in motility, GAP45 or glideosome 
associated protein 45 (39).  This protein is present in the latter stages of the erythrocytic cycle, 
specifically the schizont phase leading towards merozoite egress.  GAP45 undergoes methods of 
post-translational modification including myristoylation, palmitoylation, and even 
phosphorylation during schizont maturation and cell division (39).  The plasma membrane 
surrounding each merozoite associates with GAP 45 and the inner membrane complex whilst 
aiding schizont rupture (39).  Ultimately, invasion is a multi-tiered, cyclical process involving 
the expression of genes necessary for continued growth and development of the parasite.  The 
transmission of malaria continues when another mosquito pierces the skin and takes up the 
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waiting gametocytes in the blood of the host to start the cycle over again.  Drug and vaccine 
development target these three phases of the parasite life cycle, which contribute to the clinical 
manifestations of malaria. 
 
Signs and Symptoms of Malaria 
Any pathogen that invades the human body causes a physical and cellular change in 
efforts to rid the system of foreign invaders.  Human immunity is designed to recognize non-self; 
however, Plasmodium parasites exploit that and in doing so, cause many deleterious side effects 
to the host.  This can be complicated further in immuno-compromised individuals or in those 
patients with co-infections, such as HIV and malaria.  In uncomplicated malaria, symptoms of 
headache, nausea, muscle/joint pain, malaise, and fatigue appear before the classic symptom of 
fever (6).  Severe malaria is characterized by signs of high anemia, metabolic acidosis, organ 
failure, cerebral malaria, seizures, coma and eventually death (6, 31).  Anti-malarial therapy is 
necessary before it reaches a fatal point, although treatment of severe malaria may still lead to 
blindness and other neurological disorders such as speech impairment and deficient motor 
function (6).  These clinical outcomes are additionally explained by the genetics and cellular 
biology of the host-parasite interaction.  For the purposes of this study, we focus our attention on 
the erythrocyte stage and the molecular mechanisms as well as intrinsic factors that may alter 
Plasmodium development.  This may provide clues to understanding what affects gene 
expression in the parasite and the host response to disease persistence.  
Anti-malarial Drugs: Treatment & Prophylaxis 
Currently, no vaccine exists to prevent infection and widespread resistance to anti-
malarial drugs is emerging as a major threat to elimination efforts, supporting the need for new 
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drug discovery and development projects.  At present, drug targets are largely aimed at the 
intraerythrocytic or blood stage phase of development.  Chloroquine was used as the front line of 
treatment for P. falciparum malaria, but resistance has made monotherapies obsolete and 
combination drugs a requirement (19).  Artemisinin, like chloroquine interrupts the production of 
hemozoin in the parasite’s food vacuole, affecting further development (32).  ACTs or 
artemisinin combination therapies have been more effective since they have different 
mechanisms of action and target multiple cells/pathways (19).  In addition to chloroquine, other 
quinine derivatives exist such as mefloquine, amodiaquine, piperaquine, primaquine, 
halofantrine, and lumefantrine to name a few (24).  These anti-malarial drugs are largely 
involved in affecting the parasite’s ability to digest hemoglobin.  When combined with 
derivatives of artemisinin, they are effective in killing erythrocytic stages of P. falciparum and 
reducing parasitemia (32).  Antifolate drugs like sulfadoxine-pyrimethamine and proguanil target 
folic acid synthesis in the parasite’s cytosol and atovaquone, which inhibits mitochondrial 
processes can be used in conjunction with proguanil to affect multiple sites (5, 19, 24).  
Mechanical and chemical means of prophylaxis have been suggested as ways to prevent malaria 
transmission and re-infection.  These include, but are not limited to: insecticide-treated bed 
nets/tarps, mosquito control through indoor spraying, vitamin supplementation and (IPTp) 
intermittent preventive therapy in pregnancy using sulfadoxine-pyrimethamine (19).   
 
Drug Discovery 
The sequencing and annotation of the P. falciparum genome helped support more 
advanced studies in malaria biology, facilitating transfection and gene knockout strategies to 
characterize important genes.  These tools are considered to be important in validating drug 
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targets, especially by introducing resistance alleles in otherwise sensitive parasites.  Two major 
parts of drug discovery are target identification and validation for which phenotype screens are 
effective in determining leads (22).  Potential hits or inhibitory molecules detected from this 
strategy typically have antagonistic effects on the intracellular target (organelle, metabolism, cell 
viability, etc.) so that novel antimalarials are found [22].  Much of malaria biology is still not 
well understood, although the search for new drugs continues as more studies are conducted to 
identify important metabolic processes and pathways.  Clinical disease results from recurrent 
asexual development of the malaria parasite in the blood stage, which depends on a progressive 
pattern of gene expression widely believed to be embedded into the genome.  It is thought that 
such activities of regulating transcription and translation are vital for P. falciparum and necessary 
for efficient growth of the parasite.   
 
Fever Patterns in Malaria 
A hallmark symptom of malaria is the regular cycles of fever and chills known as 
paroxysms.  Plasmodium falciparum is a tertian malaria where every 48 hours the fever episode 
coincides with completion of the asexual cycle where schizont rupture in a process referred to as 
egress to release the invasive merozoite stages that initiate another round of intraerythrocytic 
asexual development.  Along with the merozoites all of the debris from parasite development, 
including hemozoin and LPS-like molecules, are released into the infected person’s blood (23, 
46).  This bursting also denotes that the parasitemia or percentage of parasites in the blood has 
increased exponentially.  According to Kwiatkowski & Greenwood, the fever cycle has been 
known to synchronize the protozoan population, whereby young parasites are selected to 
continue growth and replication (26).  This discovery has led to the development of antipyretics, 
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which may reduce disease progression when used in combination with artemisinin and its 
derivatives (27).  Other Plasmodium species promote fevers that occur every 72 hours (quartan 
malaria) as seen in P. malariae.  During fever, where temperatures fluctuate between 37°C and 
40°C, the sleep patterns of infected humans are disturbed further affecting synchronicity and 
parasite transmission (26).   
Release of toxins such as the hemozoin and LPS-like molecules from the bursting 
schizont stimulates innate immune response mechanisms.  In malaria pathogenesis, these host 
immune responses include proinflammatory cytokines, such as TNFα, IL-1, IL-6, IL-12, and 
complement factor 5a promote the fever associated with the paroxysm (36, 41).  Pathogen-
associated molecular patterns or PAMPs are activated by the LPS-like molecules, which have 
glycosylphosphatidylinositol (GPI) membrane anchors, to elicit cytokine and nitric oxide 
synthase response [41].  The host cells contain damage-associated molecular patterns such as 
heme, uric acid, and microvesicles that interact with these PAMPs (15).  Fever causes cellular 
and molecular changes that can be linked to transcriptional overexpression of genes exposed to 
heat shock (36).  
 
Heat Shock Proteins in Malaria 
Fever is part of the human innate immune response since prolonged periods of elevated 
temperature can be harmful to microbes and can have a significant effect on the malaria parasites, 
too.  The human immune-induced fever heat shock is not the only time P. falciparum experiences 
a drastic temperature fluctuation except when the parasite shifts from the mosquito host to the 
human and back (21).  Elevated body temperature results in the unfolding of proteins, cell cycle 
arrest, and structural changes in the cell membrane.  Consequently, episodes of elevated 
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temperature are associated with concomitant ‘parasite defense’ responses that are seen as 
variations in Plasmodium gene expression.  Molecular chaperones, specifically heat shock 
proteins (HSP), help to fold these proteins and prevent aggregation that can reduce cell viability 
[34, 35].  Previous studies comparing in vitro culturing at 37°C and 41°C, has revealed a set of 
genes that may be involved in temperature regulation.  Proteins encoded by these genes 
participate in various biological processes such as stress response, DNA repair, trafficking, 
protein secretion, transcription, signal transduction, and cytoskeleton formation to name a few 
(35).   They were compiled from gene expression data and comparative sequence analysis so that 
Hsp70, Hsp90 and others display increased expression (35).  These proteins are necessary for 
parasite survival during febrile episodes, where the heat shock response induces transcription and 
alters protein synthesis (30).   
The six Hsp-70s that occur in P. falciparum are responsible for protein transport or 
trafficking as well as folding and they are located in various parts of the cell (42).  According to 
Shonhai, these Hsps may be drug targets that inhibit the import and export of malarial proteins to 
the erythrocyte surface or disrupt the interaction with Hsp90 or Hsp40 (42).  There are four 
classes of Hsp40s in the 49-member family of which some contain the PEXEL or Plasmodium 
export element sequence and are expressed early in development (37).  Under febrile 
temperatures, Hsp40s are also upregulated like Hsp90s which modulate gene expression during 
development, heat shock factors, and the activities of protein kinases (7).  Common inhibitors to 
Hsp70 and its co-chaperones Hsp40 and Hsp90 include pyrimidinones, ATP analogues such as 
napthoquinones and tetraprenylated alkaloids, and the antibiotic Geldanamycin (21).  
Pyrimidinones alter the role of Hsp70s in presenting antigens on the cell surface and in 
stimulating NFκB signaling, while ATPase activity and protein aggregation is inhibited by “ATP 
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mimics” (21).  Geldanamycin blocks Hsp90 binding and can be effective in attenuating P. 
falciparum growth.  Environmental stressors like heat and responses to nutrient starvation both 
employ the use of such chaperones to protect the parasite, and can thus be sites for new 
antimalarial drugs.    
 
Other Stress Responses in Plasmodium  
As previously discussed, heat shock proteins are activated when a rise in temperature is 
experienced.  This can lead also to reduced protein ubiquination, decreased transcriptional 
regulation and DNA replication.  It has been reported that Hsp90 plays a role in early stage 
development from ring to trophozoite during cyclical fever episodes and is necessary for 
adaption to heat stress (33).   
Oxidative stress also induces cellular changes in P. falciparum.  This protozoan is capable 
of siphoning antioxidants from the host in conjunction with its own redox system, and slows its 
life cycle by 4 hours in the presence of increased oxygen (33).  Such a variation in the 
environmental conditions of malaria resulted in down-regulation of genes involved in amino acid 
metabolism and glycolysis, as well as an up-regulation of heat shock and DNA repair proteins.  
Nutritional stress or a paucity of sufficient amounts of isoleucine causes phosphorylation events 
during intra-erythrocytic growth that affects the expression of protein kinases important for 
signaling (33).   
 
Transcription and Gene Expression in Eukaryotes  
The regulation of transcription is necessary for proper growth of P. falciparum.  The 
expression of genes in any organism involves a multi-step process of transcription, translation, 
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and posttranslational modifications.  RNA transcription involves the use of promoters, three 
types of RNA polymerases, and a host of other transcription factors.  The asexual stages of 
Plasmodium from ring to trophozoite to schizont (G1/G2/M) occur inside the red blood cell, 
during which genes are transcribed in a rolling cascade (8, 28).  Currently, most attention in 
malaria research is focused on transcriptional regulators of gene expression and a lot of our 
understanding of P. falciparum gene regulation still comes from studies on genes involved in 
antigenic variation or var, which undergo differential expression events to evade the immune 
system and persist in the host (40).  Most of these studies support regulation of transcription in P. 
falciparum as essential in determining when genes are activated or not.  However, post-
transcriptional modifications may also alter the expression of genes and in many eukaryotes 
messenger RNA (mRNA) stability controlled through mRNA decay pathways determines the 
amount of transcripts available for translation (45).  Such regulatory mechanisms serve to 
stabilize mRNA and involve adding a 5’ cap and poly-adenylated tail or conversely removing 
them to degrade transcripts (18, 45). 
Each process involves various checkpoints and regulatory steps that control the timing 
and rate of expression.  The eukaryotic system is very complex, engaging many proteasome and 
exosome associated processes, to turn on and off different genes at different times.  This speaks 
to the multi-functionality of cells in eukaryotes that depend on timing and transcript levels to 
generate a viable gene product.  In many eukaryotes, the CCR4-NOT complex and other 
interacting partners are critical functional components regulating this mRNA stability.  The 
processes regulated by the CCR4-NOT complex are poorly understood in P. falciparum and this 
is the focus of my research plan. 
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CCR4-NOT Complex  
The CCR4-NOT complex is a eukaryotic gene regulatory system best characterized in 
yeast, yet poorly understood in Plasmodium falciparum.  The CCR4-NOT complex is involved 
in multiple aspects of mRNA metabolism and consists of five NOT proteins among other 
subunits.  NOT stands for Negative On TATA-less promoters, which in yeast act as 
transcriptional repressors (11).  Proteins of the NOT family are responsible for blocking the 
attachment of TATA binding proteins to genes that lack the promoter sequence TATA (1).  The 
single NOT1 protein of Saccharomyces cerevisiae is essential and cannot be knocked out as this 
would lead to a reduction in growth and loss of viability for yeast (11).  In P. falciparum, 
PF3D7_1103800 is unexpectedly one of two NOT1 proteins that exist (the KO we have already). 
 
PF3D7_1103800 (NOT1) and Comparison to Other Homologs  
The NOT1 protein or PF3D7_1103800 is an important feature of the CCR4-NOT 
complex.  Plasmodium are unusual in that they have two distinct NOT1s that appear to be co-
expressed in all stages studied (28).  The amino acid sequences of the NOT1 domain were 
aligned and examined for conserved regions.  Both NOT1 contain binding sites for other 
members of the complex on their N-terminal (CCR4 - CAF1) and the C-terminal (NOT2 – 5) 
regions, suggesting the second NOT1 (PF3D7_1417200, formally known as PF14_0170) may be 
functionally compensating for the PF3D7_1103800 gene disruption.  
Further genetic characterization of the PF3D7_1103800 NOT1 would be useful to help 
fill a critical gap in our knowledge of parasite growth and development.  Unfortunately, the 
current technical limitation on P. falciparum gene manipulation severely limits detailed targeted 
genetic analysis of this very large gene. In lieu of this, the proposed project will characterize 
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differences between the CAF1 KO phenotype and the PF3D7_1103800 NOT1 KO.  In addition, I 
will phenotypically screen a mutant library for potential interacting partners.  These experiments 
may elucidate how the CCR4-NOT complex operates during development through defined 
interacting proteins and the significance of its biological function. 
 
Previous studies involving the CAF1 mutant 
In the process of a whole genome random insertional mutagenesis of P. falciparum, genes 
implicated in nucleic acid metabolism were found to be especially sensitive to disruption leading 
to attenuation of asexual blood-stage growth.  One of the important regulators of P. falciparum 
gene expression we identified was the CAF1 protein of the CCR4-NOT complex.  The CCR4-
associated factor 1 or CAF1 is located on the N-terminal end of the CCR4-NOT complex and is 
involved in gene regulation during parasite egress (4).  This process occurs in the latter stages of 
growth, where a schizont bursts and the invasive merozoites leave the ruins of the red blood cells 
to find new erythrocytes to invade.  The CAF1 mutant manipulates this bursting, altering the red 
blood cell membrane prematurely, and rendering egress incomplete.  According to Balu and 
others, the merozoites of such schizonts are unable to invade causing an altered state of parasite 
development (4).  Sequencing the genome of PF3D7_0811300 CAF1 knockout (KO) mutant 
detected no SNPs or INDELs to confirm the mutant phenotype was due to disruption of 
PF3D7_0811300 (genetic complementation for phenotype rescue was not possible).  My 
experimental plan will extend this discovery to analyze a KO of PF3D7_1103800 (NOT1), 
which is the major scaffold holding together the CCR4-NOT complex. 
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piggy Bac  Mutagenesis  
The piggyBac transposon mutagenesis system provides a powerful tool for disrupting 
genes in P. falciparum as well as for rapid stable integration of transgenes for analyzing 
expression patterns (2, 3).  The system uses a transposable element to create single random 
insertional mutations in each organism’s genome, creating multiple distinct mutants that can be 
screened for potential drug targets.  The piggyback transposase identifies the TTAA sequence in 
a genome where it inserts the element as well as duplicates that TTAA site, leading efficiently to 
disruption of that locus in the parasite (2).  The ability to perform transposon-mediated 
insertional mutagenesis in P. falciparum provides a solid platform for carrying out several 
genetic analyses not previously available for Plasmodium.  When evaluating mutant genotypes 
for the rescue of wild-type phenotypes, such transgene analysis is particularly important.  Such 
innovative technology can be used for phenotypic screens to scan for important genes that 
function in parasite survival during intraerythrocytic development. 
 
TraDIS-QISeq System 
Transposon-directed insertion-site sequencing or TraDIS can be used to analyze mutant 
libraries. TraDIS is a system that can properly identify insertion sites in transposon mutagenesis 
through the generation of sequence reads along the insertion (29).  Such a method is quite useful 
with high-throughput screens needed to determine essential genes and other genetic factors 
involved in pathophysiology.  Genomic DNA from mutant pools is sent for sequencing, allowing 
for the enumeration of insertions that can make the mapping of phenotypes possible.  TraDIS can 
pinpoint the mutants that survive screening and compare them so that novel drug targets can be 
derived (29).  In other words, input mutant pools that are exposed to in vitro culture conditions, 
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in the case of P. falciparum, are compared with output pools of the mutants that remained after 
experimental treatment (10).  Attenuated mutants can be identified and a fitness score is provided 
as a log2-fold change in sequence reads between the input and output pools covering each 
insertion (10).  As next generation sequencing improves, designations for these techniques may 
also evolve.  A modified TraDIS method, known as Quantitative Insertion Sequencing (QISeq), 
was developed specifically for the transposon piggyBac in eukaryotic organisms. QISeq 
continues to identify and quantify insertions that for a piggyBac mutagenesis study in the mouse 
could numerically characterize phenotypic patterns in tissue (38).   
 
Research Focus  
Newly sequenced Plasmodium genomes have increased our knowledge of biological 
systems and function of malaria parasites.  Various gene annotation strategies serve to improve 
the flow of information from the laptop to the bench top to treatments; however, many 
hypothetical proteins still exist in this haploid parasite limiting our ability to bioinformatically 
identify vulnerabilities and critical functional partners in P. falciparum pathways.  Functions of 
most genes annotated in the genome are unknown but forward genetic analysis will overcome 
this obstacle to help link genes with the critical processes that control parasite development, 
leading to the discovery of more effective treatments.   
Phenotype screens and other methods of genetic validation can be invaluable tools to 
improve efforts of target drug discovery that may identify different vulnerable pathways and 
develop chemotypes with novel effector mechanisms.  My research project used a large-scale 
phenotype screen of piggyBac mutants to identify genetic factors associated with altered 
sensitivity to heat shock.  The factors associated with increased sensitivity to heat shock 
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represent potential targets for drug discovery during malaria fever.  In addition, my studies have 
included the functional characterization of NOT1 in erythrocytic stages of P. falciparum, which 
is a component of the putative major regulatory complex, CCR4-NOT.  
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Figure 1.1:  Global Malaria Transmission.  This map shows the transmission of malaria 
as of 2013 with the darker shaded areas containing the most cases of the disease1.  Image 
provided by http://www.who.int/malaria/publications/world_malaria_report_2014/report/en/. 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        
1 Reprinted from World Malaria Report 2014, WHO, Introduction, page No. 2, (2014). 
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Figure 1.2:  Plasmodium sp .  Life Cycle .  Malaria subsists in a mosquito host for sexual 
replication and in the human during asexual reproduction.  Image provided by 
http://www.cdc.gov/dpdx/malaria/index.html.          
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CHAPTER TWO:  
A PHENOTYPIC SCREEN OF PLA SMODIUM 
 FA LCIPA RUM PIGGY BA C  MUTANT CLONES TO IDENTIFY GENETIC 
FACTORS LINKED TO HEAT STRESS RESPONSE 
 
Introduction 
Malaria is a devastating disease that claims the lives of millions worldwide.  Nearly, 3.2 
billion people from 97 different countries remain at risk and those with the greatest risk often 
have the least access to medical treatment and testing services (18).  Since its discovery in 1880 
by Charles L. A. Laveran, ways to end disease transmission have been the top priority (4).  Once 
the vector of transmission was found to be the Anopheles mosquito, elimination of the insect and 
its reservoirs were needed.  Throughout the past century, mosquito spraying programs and 
antimalarial drug distribution have attempted to keep the disease at manageable levels.  However, 
resistant parasites and even a new species that infects people have emerged to prompt further 
study into the biology of malaria and its human host.   
The species of Plasmodium that continue their life cycle in humans include: P. falciparum, 
P. vivax, P. malariae, P. ovale, and P. knowlesi.  Plasmodium knowlesi was initially discovered 
in Southeast Asia in the 1930s and uses an intermediate or reservoir host, monkeys, to transmit 
its infective form (4, 5).  This species was formerly confused with P. malariae, but differs in its 
24-hour life cycle (4).  Interestingly, P. knowlesi was also used as a pyretic for patients with 
syphilis, when the bacterium infected the brain (5).  Pyretics or fever-inducing therapeutics have 
been utilized for years to combat injury or serious illness.  A rise in core body temperature of 1.5 
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to 5°C is typically beneficial for infected persons and requires an increase in metabolism to 
compensate (6).  The severity of the disease may affect the range and duration of febrile 
temperatures experienced by the patient and the chances of survival, leading to the use of anti-
pyretics like acetaminophen and ibuprofen (6).  However, anti-pyretics present their own 
problems in disease treatment by hampering the defense mechanism of the host.  A trade-off 
must be made between the potential damage to host tissues by fever or the immediate clearance 
of harmful pathogens.  In the case of Plasmodium sp., the asexual form of the parasite must be 
excessive enough (>100 per cubic millimeter of blood) that the fever response takes over, 
increasing the number of mononuclear cells such as TNF-producing monocytes (15).     
The most lethal of the fearsome five continues to be P. falciparum, yet drug resistance 
and new strains with shorter life cycles make these protozoans even more challenging to destroy.  
A look into human immunity and the fever response to infection may hold answers to altering 
malaria development and ending its proliferation.  A patient with clinical manifestations of the 
disease display a pattern of fever, chills, sweating, and rigor or shivering (7).  Fever onset is a 
reaction to the late stages of the parasite, schizonts, being released from the nutrient-depleted and 
malformed red blood cell.  Elevated body temperature effectively kills any remaining parasites 
that are not rings or in the early stages of development and synchronizes invasion (8, 11).  In 
response to this toxic release of parasite products, monocytes are activated and produce tumor 
necrosis factor or TNF (12, 17).  Other proinflammatory cytokines like IFN-γ are released that 
kill infected erythrocytes through nitric oxide and toxic oxygen pathways (14, 17). 
Decline in parasitemia as a result of fever is an obvious benefit.  However, the parasite 
still manages to escape total destruction and complete its life cycle. Heat shock genes may play a 
significant role in proteostasis during febrile episodes, as temperatures of 41°C lead to the 
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unfolding of proteins (10).  Identifying these and other genes in malaria that adapt to fever would 
assist researchers in finding additional candidates for blood-stage drugs.  Insertional mutagenesis 
is one method by which to conduct such an analysis and the piggyBac system offers just that.  By 
exposing the piggyBac mutant library to febrile temperature, we may be able to pinpoint genes 
that are necessary for parasite development and survival.  
 
Materials and Methods 
Plasmodium falciparum  Culturing & Maintenance 
Standard culturing methods from the Malaria MR4 manual were used.  The mutant 
library was generated in an earlier study, where the piggyBac transposase was randomly inserted 
into the genome of the parasite (1, 2).  After transfection with the piggyBac plasmid, drug 
selection of the parasite populations occurred through limiting dilution, leaving behind individual 
mutants with the piggyBac insertion.  Additionally, a complemented parasite from the piggyBac 
mutant line (C9 complement) was cultivated with 2 µg/mL Blasticidin as previously described 
(3).  The P. falciparum wild-type strain, NF54, and mutants were cultured at 37°C with mixed 
gas (5% O2, 5% CO2, and nitrogen balance) and 5% hematocrit (O+ blood from the Interstate 
Blood Bank) in complete media.  Parasites cultured at 41°C also used a tri-gas mix.  The culture 
media contains RPMI 1640 (Invitrogen) supplemented with 0.5% Albumax II (Invitrogen), 
0.25% sodium bicarbonate, and 0.01 mg/mL gentamicin.  For the heat shock portion of the 
experiment, cultures were synchronized three times with 5% sorbitol (w/v) in the ring stage. 
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Heat Shock Assay 
Malaria parasite cultures were thawed fresh according to the MR4 method and 
resuspended in complete media at 6% hematocrit.  Figure 2.1 presents an overview of the 
protocol followed for the heat shock assay of the individual mutant screen.  After a moderate 
parasitemia (1-3%) was reached, the cultures continued to grow in 5 mL flasks with complete 
media at a 5% hematocrit.  Each mutant clone was exposed to heat shock at 41°C for 8 hours.  At 
5% parasitemia, cultures were synchronized 3X with 5% sorbitol to ensure that homogeneity of 
the culture was achieved.  During this procedure, cultures were washed twice with RPMI (after a 
15 minute incubation in sorbitol with agitation) and suspended in complete media.  The first sync 
occurred during the ring stage, 48 hours or 1 cycle later, they were synchronized again and 4-6 
hours after that, the final sync took place.  The parasitemia was equalized to 3% for all cultures 
via microscopy and diluted when necessary.  Figure 2.2 depicts the cell morphology of parasite 
cultures exposed to heat shock.  Afterwards, each heat shock assay was conducted in 96-well 
plates with 3-5 piggyBac mutants and 1 NF54 wild-type culture.  Based on the modified protocol 
from Balu and others (2), 200 µL of each culture was added in triplicate wells to three plates 
labeled: T0 (time zero – start of experiment), T30 (thirty hours after start) at 37°C, and T30 (thirty 
hours after start with heat for 8 hours) at 41°C.  All plates were fixed in 0.05% glutaraldehyde in 
preparation for the flow cytometry procedure.  
 
Flow Cytometry 
Previous research using flow cytometry on P. falciparum cultures demonstrated that 
parasitemia can be estimated (9, 13).  These methods were adapted for our work and are briefly 
described here.  After fixation in 0.05% glutaraldehyde in PBS, the plates were placed at 4°C for 
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1 hour.  The supernatant was removed after centrifugation (450 x g for 3 minutes), and the pellet 
was incubated in 0.3% Triton-X 100 for 10 minutes.  Once permeabilization concluded, the 
plates were washed in PBS.  Next, there was a one-hour incubation in 0.5 mg/mL RNAse A, 
followed by 1 hour of staining with 0.1 mg/mL ethidium bromide both at 37°C.  The plates were 
centrifuged and the pellet was resuspended in PBS, where it was further diluted in order to be 
analyzed by the Accuri C6 Flow Cytometer®.  This system uses a 485 nm laser that measures 
forward light scatter to count cells and emission signals in the FL1 and FL2 channels (2).  
Infected cells were differentiated from un-infected cells by gating, where intense signals were 
seen in populations in the FL2 channel for ethidium bromide or DNA stains (Figure 2.3A).  In 
each well, 50,000 cells were counted and the data was analyzed on CFlow sampler software.    
 
Statistical Analysis 
In order to measure variation in growth for the heat shock assay, changes in parasitemia 
between 37°C and 41°C were acquired for mutant and wild-type cultures.  The average fold 
change for each parasite at 37°C was compared with the average fold change in cultures at 41°C 
(Figure 2.3B).  Data was assembled from a one-way ANOVA of normalized log values and 
Dunnett’s multiple comparisons test on Prism software (GraphPad).  Statistical significance was 
determined for samples with a P-value of 0.05. 
 
Bioinformatics Analyses of piggy Bac  Mutants 
Using a comparative genomic approach, we can analyze the sequences of many genes 
through multiple sequence alignments of P. falciparum and other species.  Sequence information 
was gathered from the NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and PlasmoDB 
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(http://plasmodb.org/plasmo/) Version 24 databases.  The amino acid sequences were put into 
databases identifying conserved domains like SMART (http://smart.embl-heidelberg.de) that can 
lead to pathway and protein interaction (http://string-db.org) data.  Such biological networks can 
be analyzed wherein protein domains are weighted with an expectation score that indicates the 
likelihood of a particular domain interaction causing certain observed protein interactions (19).  
Domains with a higher expectation score would typically provide greater confidence in the 
protein interaction that is identified. Also, a previous study using the analysis of domain 
interactions can predict protein interactions in P. falciparum (20).  Gene ontology or GO 
annotations can further reveal functional relationships between protein pairs as noted with this 
online application (http://go.princeton.edu/cgi-bin/GOTermMapper).  Additionally, a gene 
network cluster analysis was conducted using GO terms for the biological process and cellular 
compartment of the genes through enrichment mapping in Cytoscape software.  
 
Results 
  Development of an Individual Heat Shock Screen 
Plasmodium falciparum piggyBac mutant parasites were subjected to heat shock stress in 
vitro to investigate factors responsible for maintaining growth during fever-like conditions.  We 
used a piggyBac mutant library to associate altered phenotypic effects of febrile temperature to 
specific genotypes.  A list of mutants used in the individual screen for the heat shock phenotype 
is shown in Table 2.1.  The gene ID and description is provided along with their growth 
attenuation category at 37°C from previous studies (see also supplementary data in reference 2).  
The basis of this analysis began with an earlier published study involving P. falciparum wild-
type cultures exposed to hyperthermic temperatures (11).  Elevated temperature inhibits growth 
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of the parasite, especially at trophozoite and schizont stages, whereas ring stage parasites survive 
at 41°C for up to 24 hours.  Since there is not a severe drop in ring stage parasite viability until 
after 8 hours, our phenotype screen used one round of heat shock for 8 hours at 41°C to simulate 
a fever episode, with the cultures returning to 37°C or core body temperature for the remainder 
of the life cycle.  Under microscopy, the NF54 wild-type and other mutant cultures continue to 
grow after heat shock.  Yet, there are signs of crisis with less segmentation of the nuclei at the 
schizont stage, potentially leading to pyknotic forms.    
 
Heat Shock Induces Growth Changes in piggy Bac  Mutants 
There were forty-nine P. falciparum mutants randomly selected from the piggyBac 
library that underwent individual heat shock treatment.  Included in that list of parasites are the 
wild-type and C9 complement, which were also assessed for growth changes.  Fold change in 
parasitemia was compared between cultures at 37°C and those at 41°C, so that a plot shows 
parasites on the x-axis and fold change growth on the y-axis (Figure 2.4).  Out of the parasites 
tested, three were shown to have a statistically significant increase in growth after heat shock.  
These mutants are involved with export and trafficking of proteins along with protein 
metabolism and modification processes.  Twenty mutants had a statistically significant decrease 
in growth after heat shock, of which many participate in transcription, nucleic acid metabolism, 
and structural maintenance of the cell as seen in Table 2.2.  One of these sensitive or decreased 
growth mutants was the C9 mutant, a protein phosphatase involved with the cell cycle.  The 
remaining parasites had no significant change in growth and are largely conserved proteins of 
unknown function with some involved in export and signal transduction.  The C9 complement 
also had no statistical change in growth after heat shock, confirming the rescue of the original or 
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wild-type phenotype.   
 
Bioinformatics Reveal Functional Relationships between Mutants in 
Individual Screen 
The use of bioinformatics techniques allows for comparative sequence analysis of the 
mutants used in this phenotype screen.  Phylogenetic relatedness and structural characteristics 
can be examined.  With the GO Term Mapper, certain genes in our library were found to be 
associated with numerous biological processes (Figure 2.5).  The PfEMP1 family of var genes 
are linked to cell adhesion and symbiosis through parasitism as well as cytoadherence.  
Cytoadherence is a mechanism in severe malaria where parasitized red blood cells stick or 
adhere to the vascular endothelium causing blockage in various organs (16).   
In a previous study from the Adams lab, where certain genes from the piggyBac mutant 
library were tested for the cytoadherence phenotype, it was revealed that some mutants were 
increased in their binding to CHOCD36 cells (unpublished data).  Of these, one was an asparagine 
rich protein, the C9 or protein phosphatase mutant and mostly conserved proteins of unknown 
function.  The few mutants that were increased in growth after heat shock are drug transporters, a 
PHIST family protein, and a Plasmodium protein of unknown function.  The PHIST family 
includes exported proteins associated with the PEXEL translocon that interact with the 
cytoskeleton of the red blood cell.  The mutants that had decreased binding were conserved 
proteins of unknown function, one var gene as well as those involved in gene expression 
regulation, such as CAF1 and a repressor of MAF1.  Interestingly, the mutants with lower 
cytoadherence were mostly involved in nucleic acid metabolism, and in the heat shock assay the 
decreased growth mutants were also involved in nucleic acid metabolism with others 
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participating in trafficking/signal transduction and structural or membrane integrity.  The two 
other var genes exposed to febrile temperatures showed no statistical change in growth.  The 
phenotype differences in var genes may have more to do with where the transposon inserted than 
with their function.  The decreased var mutant has the piggyBac insert in the middle of its 
PFEMP domain, while the un-changed vars have the insertion either before or after the PFEMP 
domain. 
Furthermore, the increased growth mutants are likely associated with metabolic pathways 
that participate in transport, export, and oxidative phosphorylation, respectively.  Most of the 
decreased growth mutants are involved in RNA binding/synthesis, fatty acid metabolism and 
signaling, as well as membrane or cellular structure organization.  The phylogenetic analysis of 
these mutants revealed that the highest degree of conservation lies with other species of 
Plasmodium and with the PAT drug transporter, Acyl-CoA synthetase, kelch, splicing factor 3A 
subunit 2, and histone methyltransferase in some Apicomplexans such as Cryptosporidium sp. 
and Theileria sp.  Acyl-coA synthetase is a member of the fatty acid metabolism pathway and is 
one of the decreased growth mutant clones that mediates small molecule and lipid metabolism.  
Figure 2.6 also provides a network of interacting proteins among the heat shock-treated parasites 
and their potential functional partners as well as an enriched network cluster of GO terms. 
   
Discussion 
Fever is a natural process by which we fight infection and eliminate the later stages of 
malaria parasites.  Just as the search for natural products to combat infectious disease is 
underway, so to is the work to understand how innate immune mechanisms interrupt or end 
intracellular parasite development.  The methods by which P. falciparum utilizes to evade 
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immune detection is impressive, yet a more common denominator in this host-pathogen 
relationship is how elevated host body temperatures destroy the parasite or disrupt 
intraerythrocytic reproduction.  Developing a drug to act on mechanisms that enable parasites to 
survive cyclical occurrences of 41°C would be quite beneficial.  To identify such potential 
targets we developed an in vitro heat shock assay based upon previous studies from the Oakley 
study that demonstrated increased temperatures inhibit intraerythrocytic growth of P. falciparum 
(11).  Ring stage parasites survive malaria fever, while later stages (trophozoites and schizonts) 
are killed.  P. falciparum cultures grown at 41°C for more than 32 hours caused death in 100% of 
the parasites.  Asynchronous and synchronous cultures exposed to this temperature for 2 – 8 
hours, saw reduction in growth correlate to time incubated at 41°C, yet viable parasites remained 
(11).  With that in mind, we cultured our pooled mutants at 41°C for 8 hours every 48 hours, the 
length of the erythrocyte cycle in tertian malarias and returned them to 37°C in between heat 
shocks to follow the fever pattern.   
The heat shock assay employed here is one way to mimic intracellular fever and identify 
those genes which may act synergistically with this process to enhance parasite death.  We 
discovered that many of these genes function in transport, nucleic acid and protein metabolism as 
well as signal transduction (Figure 2.7).  The highest cluster frequency was seen in genes 
associated with gene expression, RNA metabolism and processing, nucleic acid metabolism, the 
macromolecular complex, and cellular nitrogen metabolism.  The genes of note had only growth 
affects due to heat shock and were increased or decreased significantly after this exposure. 
Determining whether these mutants are associated with key functions and gene regulatory 
processes can be useful in drug discovery during asexual development for P. falciparum.  
Bioinformatics revealed that many of these genes are associated with cell maintenance and 
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protein modification, which is to be expected if they are to survive host fever. The members of 
the CCR4-NOT transcription complex, CAF1 and NOT1, are also linked to a cluster with RNA 
pseudouridylate synthase.  The asparagine rich protein is connected with merozoite surface 
proteins that also have a link with the transcription factor with AP2 domains (ApiAP2).  There 
are many Gene Ontology (GO) identifiers associated with increased or decreased sensitivity to 
heat shock.  As noted earlier, the increased growth mutants or those with decreased sensitivity to 
heat shock are structural/membrane proteins, exported proteins, and proteins involved with 
protein modification.  In addition to the conserved proteins of unknown function that are un-
changed after heat shock, there is a gene (PF3D7_0619900) in the spliceosome complex that 
interacts with heat shock protein 60.  A HSP70 is also found to associate with RNA 
pseudouridylate synthase, a protein involved in nucleic acid metabolism.   There are additional 
genes in the piggyBac mutant library that can be evaluated for the heat shock phenotype.  These 
and others genes may hold the key to unlocking mechanisms of fever adaptation.  
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Figure 2.1: Heat Shock Assay Procedure .  This flow chart depicts the setup for the 
individual heat shock screen as conducted in 96-well plates.  T0 plates represent the ring stage or 
beginning of the experiment.  T30 plates at 37°C represent the controls and T30 plates at 41°C are 
the hyperthermic temperature-treated samples. 
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Figure 2.2: Morphology of Cultures under Heat Shock Treatment.  Microscopic 
view of P.falciparum NF54 WT infected red blood cells.  Images are from cultures at 37°C and 
41°C for 8 hours.    
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Table 2.1:  Individual Screen Mutant List. The information provided on their functional 
and attenuation categories was adapted from previous work with a genetic screen of these P. 
falciparum mutants in reference 2.  In the attenuation column, S = severe, N = non-attenuated, 
and M = moderate.  
PlasmoDB Gene ID Gene Description Functional Category Attenuation 
Category 
PF3D7_1360200  Conserved protein, 
unknown function 
Nucleic acid 
metabolism/Nucleic 
acid 
binding/Transcription 
S 
PF3D7_1133700  Conserved Plasmodium 
protein, unknown 
function 
Nucleic acid 
metabolism/Nucleic 
acid 
binding/Transcription 
S 
PF3D7_1227800  Histone S‐adenosyl 
methyltransferase, 
putative 
Nucleic acid 
metabolism/Nucleic 
acid 
binding/Transcription 
S 
PF3D7_0830900  Plasmodium exported 
protein, unknown 
function 
Conserved proteins 
with unknown function 
S 
PF3D7_0811300  CCR4‐associated factor 1 
(CAF1) 
Membrane/Structural 
proteins, trafficking 
and signal transduction 
S 
PF3D7_1103800  CCR4‐NOT transcription 
complex subunit 1, 
putative (NOT1) 
Nucleic acid 
metabolism/Nucleic 
acid 
binding/Transcription 
S 
PF3D7_0731600  Acyl‐coA Synthetase  Biochemical 
pathways/proteins 
metabolism/protein 
modification 
S 
PF3D7_1305500  Protein phosphatase, 
putative 
Cell cycle/Biochemical 
pathways/protein 
metabolism/protein 
modification 
S 
PF3D7_0622900  Transcription factor with 
AP2 domain(s), putative 
(ApiAP2) 
Nucleic acid 
metabolism/Nucleic 
acid 
binding/Transcription 
S 
PF3D7_0402000 
 
Plasmodium exported 
protein (PHISTa), 
unknown function 
Exported Proteins  N 
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Table 2.1:  (Continued) 
PlasmoDB Gene ID  Gene Description  Functional Category  Attenuation 
Category 
PF3D7_1345800  Conserved Plasmodium 
protein, unknown 
function 
Conserved proteins 
with unknown function 
N 
PF3D7_1444100  Conserved Plasmodium 
protein, unknown 
function 
Biochemical 
pathways/protein 
metabolism/protein 
modification 
N 
PF3D7_1328700  Plasmodium RNA of 
unknown function, RUF1 
Plasmodium RNA with 
unknown function 
N 
PF3D7_1219300  Erythrocyte membrane 
protein 1, PfEMP1 (VAR) 
Exported Proteins  N 
PF3D7_1231800  Asparagine‐rich protein, 
putative 
Conserved proteins 
with unknown function 
N 
PF3D7_1475700  Tubulin epsilon chain, 
putative 
Membrane/Structural 
proteins, trafficking 
and signal transduction 
 
N 
PF3D7_1004600  Conserved Plasmodium 
membrane protein, 
unknown function 
Conserved proteins 
with unknown function 
N 
PF3D7_0808700  Erythrocyte membrane 
protein 1, PfEMP1 (VAR) 
Exported proteins  N 
PF3D7_0619900  Splicing factor 3A subunit 
2, putative (SF3A2) 
Nucleic acid 
metabolism/Nucleic 
acid 
binding/Transcription 
N 
PF3D7_1411100.1  Conserved Plasmodium 
membrane protein, 
unknown function 
Conserved proteins 
with unknown function 
N 
PF3D7_0931000  Elongation factor Tu, 
putative 
Biochemical 
pathways/protein 
metabolism/protein 
modification 
N 
PF3D7_1018300  Conserved Plasmodium 
protein, unknown 
function 
Conserved proteins 
with unknown function 
N 
PF3D7_0416500  Repressor of RNA 
polymerase III 
transcription MAF1, 
putative 
Conserved proteins 
with unknown function 
N 
PF3D7_1441800  Vacuolar‐sorting protein 
SNF7, putative 
Membrane/Structural 
proteins, trafficking 
and signal transduction 
N 
  38 
Table 2.1:  (Continued) 
PlasmoDB Gene ID  Gene Description  Functional Category  Attenuation 
Category 
PF3D7_1141900  Inner membrane 
complex protein 1b, 
putative (IMC1b) 
Membrane/Structural 
proteins, trafficking 
and signal transduction 
N 
PF3D7_0521900  Conserved Plasmodium 
protein, unknown 
function 
Conserved proteins 
with unknown function 
N 
PF3D7_1333400  Conserved protein, 
unknown function  
Conserved proteins 
with unknown function 
N 
PF3D7_1343700  Kelch protein, putative  Membrane/Structural 
proteins, trafficking 
and signal transduction 
N 
PF3D7_1122900  Dynein heavy chain, 
putative 
Membrane/Structural 
proteins, trafficking 
and signal transduction 
N 
PF3D7_0404600  Conserved Plasmodium 
membrane protein, 
unknown function 
Conserved proteins 
with unknown function 
N 
PF3D7_0511500  RNA pseudouridylate 
synthase, putative 
Nucleic acid 
metabolism/Nucleic 
acid 
binding/Transcription 
N 
PF3D7_1432400  Leucine‐rich repeat 
protein (LRR5) 
Conserved proteins 
with unknown function 
N 
PF3D7_0611800  Conserved Plasmodium 
protein, unknown 
function 
Conserved proteins 
with unknown function 
N 
PF3D7_0206200  Metabolite/drug 
transporter ‐ 
pantothenate 
transporter 
Membrane/Structural 
proteins, trafficking 
and signal transduction 
 
M 
 
PF3D7_0523200 
 
Conserved Plasmodium 
protein, unknown 
function 
Conserved proteins 
with unknown function 
M 
PF3D7_1143500  Conserved Plasmodium 
protein, unknown 
function 
Conserved proteins 
with unknown function 
M 
PF3D7_0601900  Conserved Plasmodium 
protein, unknown 
function 
Conserved proteins 
with unknown function 
M 
PF3D7_1207800  Conserved Plasmodium 
protein, unknown 
function 
Conserved proteins 
with unknown function 
M 
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Table 2.1:  (Continued)  
PlasmoDB Gene ID  Gene Description  Functional Category  Attenuation 
Category 
PF3D7_1136000  Conserved Plasmodium 
protein, unknown 
function 
Conserved proteins 
with unknown function 
M 
PF3D7_1035800  Probable protein, 
unknown function 
(M712) 
Conserved proteins 
with unknown function 
M 
PF3D7_0726000  28S ribosomal RNA  Ribosomal RNA  M 
PF3D7_1138900  Non‐protein coding, 
unspecified product 
Unspecified 
product/unknown 
transcript 
M 
PF3D7_0211100  Conserved Plasmodium 
protein, unknown 
function 
Membrane/Structural 
proteins, trafficking 
and signal transduction 
M 
PF3D7_1459500  Conserved Plasmodium 
protein, unknown 
function 
Conserved proteins 
with unknown function 
M 
PF3D7_0615900  Conserved Plasmodium 
protein, unknown 
function 
Biochemical 
pathways/protein 
metabolism/protein 
modification 
M 
PF3D7_0902200  Serine/threonine protein 
kinase, FIKK family 
(FIKK9.3) 
Biochemical 
pathways/protein 
metabolism/protein 
modification 
M 
PF3D7_0400100  Erythrocyte membrane 
protein 1, PfEMP1 (VAR) 
Exported proteins  M 
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Figure 2.3: Flow Cytometric Analysis .  A.  Parasitized red blood cells were analyzed by 
flow cytometry with gating around 30-hour populations or schizonts, the end-point of the assay.  
Populations of un-infected cells and ring-stage parasites are also defined. B.  Parasitemia was 
counted by C6 Flow software for cultures grown at 37°C and 41°C and this calculation was used 
in determining the fold change. 
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Figure 2.4: Results of  Heat Shock Assay .  The figure above represents comparative 
growth data between cultures grown at 37°C and 41°C.  The white bars denote parasites that had 
significantly increased growth, the black bars are for parasites with no statistically significant 
change in growth, and the grey bars display parasites with significantly decreased growth after 
heat shock.           
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Table 2.2:  Mutants with Heat Shock Phenotype . This table contains a list of the P. 
falciparum mutants that were resistant and sensitive to heat shock.  These mutants grew normally 
at 37°C in a previous growth screen, yet exhibit the heat shock phenotype at 41°C.  
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Figure 2.5: Graph of Mutant GO Categories .  The GO (Gene Ontology) functional terms 
associated with each mutant in the heat shock assay are compared based on whether they are 
resistant (increase in growth), no statistical change in growth, or sensitive (decreased growth). 
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Figure 2.6: Interaction Network of Heat Shock Mutants .  The cluster map above 
shows some of the piggyBac mutants used in the individual heat shock assay (highlighted in 
yellow) and their predicted functional partners.   
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Figure 2.7: Gene Network Enrichment Map.  This diagram categorizes the piggyBac 
mutants under heat shock by biological process and cellular compartment. GO terms were used 
to make the enrichment map above. Red node size corresponds to the number of genes linked to 
that GO term.  The green edge size corresponds to the number of genes that overlap in GO terms.          
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CHAPTER THREE:  
A LARGE SCALE PHENOTYPIC SCREEN OF PLA SMODIUM FA LCIPA RUM 
 MIXED MUTANT POOLS TO IDENTIFY GENETIC FACTORS LINKED TO 
HEAT STRESS RESPONSE 
 
Introduction 
As one of the three major global health concerns, malaria continues to warrant increased 
research and preventative efforts to reduce the burden of disease on endemic regions.  Hundreds 
of millions of people are infected with malaria with just under one million dying from the disease 
annually (21).  The region with the greatest number of deaths continues to be the continent of 
Africa, where children under the age of 5 make up the majority of mortality reports.  The female 
anopheline mosquito carries the protozoan parasite responsible for transmitting malaria.   One 
bite from this insect vector is all it takes to perpetuate the disease as the salivary glands contain 
thousands of infectious sporozoites of which only a few (anywhere from 5 to 500 depending on 
species) successfully proceed to development [15, 17, 20].  Five species of malaria are capable of 
infecting humans; however, P. falciparum is the deadliest malaria parasite and anti-malarial 
drugs are in high demand.  Such an infection may cause irreparable harm to the human host even 
if the outcome is not fatal.   
Fever, in particular, is the human body’s method of fighting microbial infections and the 
onslaught of other invading pathogens.  As a characteristic symptom of malaria, febrile 
temperatures can reach 41°C (or ~106°F) and occur intermittently, with some episodes lasting 6-
10 hours [3, 5, 8].  In the case of P. vivax infections, febrile episodes are not as prolonged and 
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the rise in body temperature happens under 8 hours (8).  In adults, at least 20 – 20,000 parasites 
are present in a microliter of blood during the initial febrile state (20).  As a quantitative 
phenotype, fever can be measured precisely unlike many of the other clinical symptoms 
associated with severe malaria, which are often determined retrospectively via surveys of patient 
records (10).  Parasitemia or the percentage of parasites in the blood is another quantifiable 
factor that will aid in understanding the effects of periodic paroxysms.  Understanding the 
adaptability of the protozoan parasite to evade or survive fever is the impetus for employing heat 
shock assays.  It is this phenotype that we seek to elucidate through in vitro experiments with 
malaria cultures. 
Malaria fever results from schizont rupture when various proteins, cellular debris, lipids 
(GPI anchors), and hemozoin pigments enter the bloodstream activating tumor necrosis factor 
(TNF) from monocytes [13, 20].  The TNF cytokine induces fever and is also responsible for 
increased expression of certain ligands necessary for binding in cytoadherence, an effect seen in 
cerebral malaria (8, 13, 20).  Identifying which proteins are sensitive to high temperatures of 
41°C can be useful in proposing new targets for drugs.  Heat shock proteins (as the name 
suggests) are likely candidates, yet the proteins they associate with have a wide range of 
functions.  In malaria parasite biology, these include: DNA synthesis, transport, transcriptional 
regulation, hemoglobin digestion, RNA processing, cytoskeleton organization, and more; 
reflecting the metabolic functional interactions needed for parasite survival during episodes of 
fever (11).    
An in vitro phenotypic assay developed to screen for altered responses to fever-like 
temperatures of individual piggyBac mutant clones was adapted for phenotypic screens of mixed 
mutant populations.  This phenotypic assay was used to screen complex piggyBac mutant 
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populations from a small and large library of P. falciparum mutants. These parallel phenotypic 
screens identified a set of genes whose growth was altered by periodic heat shock and may be 
essential for parasite adaptation during fever.  Carried forward this approach should provide a 
comprehensive understanding of how P. falciparum tolerate the stress of fever, which is an 
important gap in our knowledge of malaria parasite biology, and may provide the opportunity of 
discovering new drug or vaccine targets to combat malaria.  More importantly, the forward 
genetic screen approach used in this study establishes a methodology that allows for a greatly 
enhanced way to functionally profile the P. falciparum genome.  Random insertions created by 
piggyBac mutagenesis, when combined with the QIseq technique to quantitatively assess 
changes under phenotypic selection, provides a much-needed approach for analyzing genotype-
phenotype relationships.  
 
Materials and Methods 
Parasite Culture 
All cultures were grown and maintained using standard methods outlined in the Malaria 
MR4 manual.  The NF54 clone of P. falciparum was used as the parent line for all transfections.  
Individual piggyBac mutant clones were obtained by limiting dilution of parasites post-drug 
selection (2.5 nM WR99210) and a number of aliquots for each mutant clone were cryopreserved 
previously for the project study [1, 2].  The P. falciparum mutants were cultured initially at 37°C 
with mixed gas (5% O2, 5% CO2, and 90% nitrogen) and 5% hematocrit (O+ blood from the 
Interstate Blood Bank) in complete media.  This growth media consists of RPMI 1640 from 
Invitrogen supplemented with 0.5% Albumax II (Invitrogen), 0.25% sodium bicarbonate, and 
0.01 mg/mL gentamicin.  For the heat shock assay, pooled cultures were thawed fresh and grew 
  51 
asynchronously until the temperature treatment was applied.  
 
Heat Shock Assay for Pooled Mutants 
Figure 3.1A presents an overview of the heat shock assay for the large pool of PB 
mutants (the heat shock assays are based on a study by Oakley and others, [13]).  Malaria 
parasite cultures were thawed and maintained in 5 mL flasks to reach a parasitemia of 3% 
parasitemia or at minimum greater than 1%.  Flasks were labeled pool 1, pool 2, and pool 3 
corresponding to the mutants associated with those groups.  At a parasitemia greater than 1%, the 
flasks were combined into a master pool and split into 5 – 10 mL flasks.  Three flasks were 
labeled A, B, and C (triplicate samples) for the heat shock or treatment flasks.  The remaining 
two flasks were labeled D and E (duplicate controls) and were grown constantly at 37°C.  The 
treatment flasks were subjected to 41°C for 8 hours, placed back at 37°C and allowed to grow 
until the next cycle.  The second round of heat shock took place nearly 40 hours later at ring 
stage.  After 8 hours in an incubator set at 41°C, the flasks were put back at 37°C.  This process 
repeated until after the third round of heat shock, where the treatment cultures were grown to 
more than 5% parasitemia and harvested for gDNA and RNA.  The control flasks were only 
cultured at 37°C for the duration of the experiment.  When the parasitemia reached higher than 
2%, the flasks were split to avoid stress by spatial constraints or overgrowth and continued to 
grow at 37°C until gDNA and RNA was harvested at the same time as the treatment flasks, at 
least eight days later.  In addition, mutant clones of pool 1 were screened separately as a single 
pool and as individual isolated clones following a similar heat shock protocol, except the 
individual clones were exposed to only one round of heat shock and not three.  
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A subset of mutants (PF3D7_0523200, PF3D7_1227800, PF3D7_1018300, and 
PF3D7_0808700) that exhibited a different phenotype in the pool (with 3 heat shocks) versus its 
original phenotype of individual clone screen (with 1 heat shock) were assayed again. Each 
mutant clone and one NF54 WT clone were subjected to three heat shocks, only this time each 
clone was in its own flask.  At a parasitemia equalized to 1%, all cultures were initially grown in 
25 – 5 mL flasks.  Each clone had three flasks labeled A, B, and C (triplicate samples) for the 
heat shock or treatment group and two flasks labeled D and E (duplicate controls) for cultures 
grown constantly at 37°C.  The treatment flasks were gassed and heat shocked at 41°C for 8 
hours, placed back at 37°C and allowed to grow until the next cycle.  Sampling occurred after 
thirty hours at the late trophozoite/schizont stages and before each heat shock.  The second round 
of heat shock took place nearly 40 hours later at ring stage.  After 8 hours in an incubator set at 
41°C, the flasks were put back at 37°C.  Before the last heat shock, cultures were brought up to 
20 mL in T75 flasks.  This process repeated until after the third round of heat shock 
(approximately eight days later), where the treatment and control cultures were fixed in 0.05% 
glutaraldehyde for flow cytometry.  
 
gDNA Isolation 
After the phenotype assay, genomic DNA (gDNA) was collected for Illumina sequencing.  
The samples were prepared using the QIAmp DNA Blood Mini Kit (Qiagen) for extracting 
gDNA from cell cultures.  Alternatively, a modified version of gDNA isolation in Plasmodium 
was used to obtain at least 5 µg of sample material.  The assayed cultures were centrifuged at 
1600 RPM for 3 minutes and the supernatant was removed.  The pellet was resuspended in 0.5% 
saponin in TEN buffer (0.1M Tris-Cl, pH 8.0; 0.01M EDTA, pH 8.0; and 1M NaCl) and 
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vortexed.  After transfer to an Eppendorf microcentrifuge tube, the sample was centrifuged at 
high speed (10,000 x g) for 3 minutes at room temperature.  The supernatant was discarded and 
the pellet was washed three times in 1 mL TEN with a 3-minute spin in between.  Then, the 
pellet was resuspended in TEN buffer with 2% SDS and mixed well, 7.5 M ammonium acetate 
was added to the solution, vortexed, and centrifuged at 10,000 x g for 3 minutes at room 
temperature.  The supernatant is kept and transferred to a new 1.5 mL tube, where an equal 
volume of 100% isopropanol is added.  The sample is centrifuged at max speed or 14,000 x g for 
15 minutes at 4°C.  Washes in 70% ethanol and 100% ethanol take place, respectively and the 
pellet dries at room temperature until resuspension in water or TE buffer. 
 
RNA Extraction 
Once the heat shock assay was complete, RNA was extracted from the pooled cultures 
and stored for any further experiments or expression analysis.  Using a modified Invitrogen 
protocol, infected red blood cell cultures were centrifuged at 12,000 x g for 5 minutes and 
washed in 1X PBS.  Afterwards, 10% saponin was added and the tube was inverted to allow for 
mixing.  The sample was incubated at room temperature for 10 minutes.  The supernatant was 
discarded after centrifugation (12,000 x g for 5 minutes) and the pellet was washed twice with 
1X PBS.  TRIzol reagent was added to dissolve the pellet through repeated pipetting and a room 
temperature incubation for 5 minutes took place as the solution was transferred to another 
microcentrifuge tube.  Depending on the downstream application, cDNA could be synthesized or 
RNA isolation can continue with the addition of chloroform.  After a 5-minute incubation, the 
sample is centrifuged at 12,000 x g in 4°C for 15 minutes.  Only the upper phase or clear 
suspension is transferred to another tube as that contains the RNA.  The interphase or white 
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mixture contains DNA as this separation occurs when chloroform interacts with TRIzol.  
Isopropanol is added and mixed by inverting, then incubated for 10 minutes at room temperature.  
Once centrifugation at 12,000 x g (4°C) for 15 minutes occurs, the supernatant is removed and 
the pellet is washed in 75% ethanol.  After a 5-minute spin at 10,000 x g, the supernatant is 
discarded and the pellet air dries.  The RNA is resuspended in diethylpyrocarbonate (DEPC)-
treated water and stored at -80°C.   
 
QISeq Illumina Library Preparation 
The gDNA extracted from the pooled heat shock screen was sent off to the Wellcome 
Trust Sanger Institute in the United Kingdom for quantitative sequence analysis.  Their genomic 
research facility uses a modified TAIL PCR with Illumina sequencing approach to identify 
insertion sites for transposons.  This technique is termed QISeq (quantitative insertion site 
sequencing), which is a type of TraDIS or transposon-directed insertion-site sequencing, since it 
can identify quantitatively each insertion site within mixed populations of piggyBac mutants.  
There are four main steps for QISeq: library construction, initial PCR amplification, a second 
nested PCR, and the analysis (Figure 3.2).  Fragmentation of genomic DNA from the mutant 
pool occurs and a poly-A tail is added with custom splinkerette adapters (12, 19).  The QISeq 
method was developed as a collaboration between Julian Rayner (WTSI) and John Adams 
(USF); the excerpt included here is from an unpublished manuscript describing development of 
QISeq [4]. 
 “Plasmodium falciparum DNA was quantified using Qubit High Sensitivity assay 
according to the manufacturers protocol (Life Technologies Ltd, UK). Between 200 and 500 ng 
was sheared using a Covaris E210 Adaptive Focused Acoustics ultrasonicator (LGC Genomics, 
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UK) to an average size of 500 bp. The DNA was end repaired, a-tailed and adapter ligated using 
a NEBNext DNA Library Prep kit (New England Biolabs (UK) Ltd, UK). Instead of the standard 
Illumina adapter a specific adapter containing a 5’ hairpin (Splinkerette adapter) was ligated to 
the DNA.  Splinkerette adapter: top: 
5’-GTTCCCATGGTACTACTCATATAATACGACTCACTATAGGTGACAGCGAGCGCT-3’
 bottom: 5’-P-GCGCTCGCTGTCACCTATAGTGAGTCGTATTATAATTTTTTTTTCAAAA
AAA-3’ (4).  A 5’ Phosphate group (P) was added to help specific ligation of this adapter to the 
DNA library.  This Splinkerette adapter was adapted and elongated from (18) to accommodate 
Illumina sequencing and multiplexing. 
piggyBac insertion sites were acquired from the adapter ligated DNA library using two 
nested PCR reactions (PCR1 and PCR2). For this the adapter-ligated library DNA was split in 
two to amplify both the 5’ and 3’ end of the piggyBac transposon respectively into two separate 
libraries. All PCR reactions were done with KAPA KAPAHiFi HotStart (Anachem Ltd., UK). 
PCR1 conditions were as follows (SplAP1: 
5’-GTTCCCATGGTACTACTCATA-3’ with PB5-1: 5’-GATATACAGACCGATAAAACACA
TGCGTCA-3’ or PB3-1: 5’-GACGGATTCGCGCTATTTAGAAAGAGAG-3’ for 3’ or 5’ 
piggybac ends respectively; 18 cycles of PCR; annealing at 63°C; extension at 68°C [to improve 
amplification of the AT rich DNA]). These PCR1 reactions were cleaned using 0.8x volume 
Ampure XP (Beckman Coulter (UK) Ltd, UK) to remove residual PCR primers. Next a nested 
PCR (PCR2) was done for both 5’ and 3’ ends to produce libraries containing only piggyBac 
integration sequences (4).  PCR2 conditions were as follows 
(P7-SplAP2 5’-CAAGCAGAAGACGGCATACGAGATCGGTXXXXTAATACGACTCACTA
TAGG-3’; [XXX is for the reverse complement of the index] with 
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PB5-2: 5’-A*ATGATACGGCGACCACCGAGATCTACACCACGCATGATTATCTTTAACG
TACGTCA*C-3’, PB3-2: 5’-AATGATACGGCGACCACCGAGATCTACACATGCGTCAAT
TTTACGCAGACTATC-3’ for 3’ or 5’ piggyBac ends respectively; 12 cycles of PCR; 
annealing at 60°C; extension at 68°C).  Again the PCR reactions were cleaned using 0.8x volume 
Ampure XP (Beckman Coulter (UK) Ltd, UK) to remove residual PCR primers [4].  
 
QISeq Library Quality Control and Sequencing Approach   
To determine library yield, 3 individual qPCRs were done on the finished library 
using the following forward: PB5pr_seq: 5’-TGATTATCTTTAACGTACGTCACAATATGAT
TATCTTTC-3’ [piggyBac 3’ specific]; PB3pr_seq: 5’-ATGCGTCAATTTTACGCAGACTATC
TTTC-3’ [piggyBac 5’ specific]; PE2.1: 5’-AATGATACGGCGACCACCGAGATC-3’ 
[Illumina P5 sequence specific]; and reverse (PE2.2:  
5’-CAAGCAGAAGACGGCATACGAGAT-3’ [Illumina P7 sequence specific]) primers. qPCR 
conditions were standard for the KAPA HiFi qPCR kit (Anachem Ltd., UK) and all products 
were quantified relative to the defined standards from the kit [4].  For optimal loading conditions 
concentrations of the orientation specific piggyBac primers were used. Generally these were very 
similar to the Illumina P5-P7 specific product, whereas the PCR signal for the opposite piggyBac 
end always gave a much lower fluorescent signal. 
To confirm transposon integrations only, the sequencing primers were designed within 
the long terminal repeat region of the piggyBac transposon integration site 5 bases upstream of 
piggyBac integration site sequence (TTAA).  PB5pr_seq_2: 
5’-CACCGAGATCTACACCACGCATGATTATCTTTAACGTACGTCACAATATGATTATC
TTTC-3’ for the 3’ piggyBac sequence; PB3pr_seq_3: 5’-CACCGAGATCTACACATGCGTCA
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ATTTTACGCAGACTATCTTTC-3’ for the 5’ piggyBac sequence; 
Spl_rev_seq: 5’-TAATACGACTCACTATAGGTGACAGCGAGCGCT-3’ 
for the reverse sequence; and Spl_tag_seq: 5’-AGCGCTCGCTGTCACCTATAGTGAGTCGTA
TTA-3’ to determine the index sequence for multiplexing (4). Since this meant all reads started 
with the same 9 bases it interfered with Illumina’s template generation step. To skip template 
generation in the 9 bp mono-template sequence, the standard Amplicon recipe was modified. 
This modified recipe commenced the sequencing reaction with dark-cycles (cycles where 
incorporation of bases but no imaging takes place). To confirm the sequence of these omitted 
bases a separate transposon index read (index read 2) was added to the recipe. Even though this 
solved sequencing issues in other CG neutral piggyBac libraries, the genomic AT bias in P. 
falciparum resulted in Illumina’s colour matrix calling errors. To eradicate these errors, the 
libraries were spiked with low (MiSeq: 10-20%) or higher (HiSeq: 50%) amounts of a well-
defined CG neutral genomic library (i.e. PhiX) [4].” 
 
QISeq Primary Sequence Analysis 
All piggyBac mutants were generated in the strain NF54, while the P. falciparum 
reference genome is generated from 3D7 (7).  A reference genome of NF54 was therefore 
generated to increase the accuracy of insertion site calling. Illumina libraries of 400-500bp 
fragment length were generated using following the PCR-free protocol (9).  An NF54 reference 
genome was generated using a morphing approach with ICORN (16) transforming the 3D7 
genome version 3 through iterative mapping and correcting into to the NF54 genome. As 
reference we used the P. falciparum 3D7 reference from September of geneDB 
(ftp://ftp.sanger.ac.uk/pub/project/pathogens/malaria2/3D7/3D7.latest_version/version3/2014/Se
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ptember_2014/). The NF54 reference genome generated can be found at 
ftp://ftp.sanger.ac.uk/pub/project/pathogens/Plasmodium/falciparum/NF54/Assembly/V1_morph
ed. The QISeq libraries were sequenced on both a MiSeq and HiSeq2500, with 5’ and 3’ libraries 
sequenced separately. Samples were multiplexed. The read length was 75 bp and the fragment 
size around 350. These sequence reads were mapped to the NF54 reference genome. 
   
QISeq Advanced Data Analysis 
In analysing QISeq data for phenotypic effect of the heat shock, we compared relative 
abundance in mapped reads of each mutant after heat shock relative to its control held at 37 C.  
Changes of relative abundance represent a combined measure of a parasite’s growth, its 
proportion in the starting population, and the fixed read number for each Illumina sequencing run. 
Therefore to facilitate comparative analysis, the mapped sequence data were used to calculate a 
representative Fold Change (FC) of growth with and without heat shock (Fig. 3.1B).  Mutants 
that are attenuated have a negative fitness score assigned to them, while those that are not have a 
positive fitness score, indicating an excess amount of survivors in the pool (6).  Fitness scores are 
represented by fold change or log2 values between the input and output pools, where the total 
number of reads for each transposon is compared (6).  For strongly deficient mutants, sequence 
reads were unable to be mapped in the output pool, thus the amount that went in was not 
recoverable on the way out. 
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Results 
Development of a Heat Shock Screen for P. falciparum piggy Bac  Mutants 
using QISeq 
Three piggyBac mutant pools of P. falciparum clones were combined into one master 
pool and exposed to febrile temperature in order to test the effects of heat on the parasite.  Table 
3.1 lists the 126 mutants used in the heat shock assay of the master pool.  The collection of 
mutants tested had a wide diversity of GO pathways represented from conserved Plasmodium 
proteins to those involved with transcription, metabolism, transport, etc.  Growth at 37°C was 
compared to that at 41°C, where fold change was plotted for each mutant.  Phenotype screens 
help to identify possible gene targets and QISeq can be used to confirm those phenotypes.  The 
introduction of next generation sequencing techniques, like QISeq, further enhances our ability 
to discern gene function and observe their role in viability.   
 
Febrile Temperature Exposure Impacts Growth of pooled piggyBac 
Mutants 
In this study successive rounds of heat shock mirror malaria paroxysm and affect the 
growth and development of parasites with mutations in genes important for tolerating fever 
during an infection.  As anticipated, QISeq results revealed significant variations in growth of 
among only some mutants in the master pool (Figure 3.3 A & B).  Treatment cultures were 
exposed to 41°C, an elevated temperature in the human host and control cultures were 
maintained at normal body temperature or 37°C.  Fold changes of mutant growth at control and 
heat shock temperatures were compared over the course of the experiment.  A positive value for 
fold change was seen in the mutants on the left side of the bar graph and a negative fold change 
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appears on the right side of figure 3.3 B.  The sequence reads for mutants corresponded to their 
growth over 24 cycles with a cutoff value of 100, and mutants above that or increasing in read 
number are more abundant after heat shock. 
 
Bioinformatics Reveal Functional Relationships between Mutants in 
Pooled Screen 
An in silico analysis of the piggyBac mutants in the pooled screen and the individual 
screen was conducted to validate the heat shock phenotype through comparison of genes that are 
sensitive or resistant to febrile temperatures (Figure 3.4).  The heat shock response is mediated 
by genes expressed at different life cycle stages of P. falciparum.  There are gene clusters in 
figure 3.4 with higher expression in sexual stages (gametocytes and ookinetes), such as those 
involving LRR5 and IMC1b.  These genes are also important in the parasite’s adaptation to heat 
shock stress.  Figure 3.5 shows the Gene Ontology (GO) annotations that identified functional 
relationships between sets of proteins as performed with GO TERM Mapper 
(http://go.princeton.edu/cgi-bin/GOTermMapper) and the PANTHER classification system 
(http://www.pantherdb.org/).  The pooled mutants that had a positive fold change or increased 
growth after heat shock were largely dominated by genes of biochemical pathways and protein 
metabolism.  Also, conserved proteins of unknown function and export proteins were associated 
with this group.  The decreased growth mutants that had a more negative fold change consisted 
of genes involved with transcription and nucleic acid metabolism.   
The amino acid sequences of these proteins were used to find any conserved domains that 
led to interaction data and predicted associations.  Cytoscape software along with the GOlorize 
plugin was used to develop network linkages between genes.  An enrichment mapping 
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application and the BINGO program allowed for the overrepresentation of a gene set in a 
biological network based on GO terms so that the frequency of genes in a network was assessed 
(Figure 3.6).  Interestingly, the mutants in this phenotype screen were affiliated with a transport 
and cellular homeostasis cluster.  Genes involved with this cluster are heat shock genes or HSPs 
and their chaperone complexes, which maintain cellular homeostasis under conditions of 
temperature and heat stress.  Other enriched genes were in clusters involved with gene 
expression, ribosomal synthesis, RNA metabolism, and membrane transport.   
 
Discussion 
Understanding malaria fever and the genes involved in helping the parasite adapt to such 
environmental conditions serve a dual purpose.  Primarily, it provides new knowledge about 
Plasmodium biology and secondly, it offers new avenues for drug discovery.   The genes 
associated with malaria fever are numerous and exist in various compartments of the cell (14).  
By using QISeq, differentiation between mutants that were combined into one giant pool was 
made.  This technique found separate insertions corresponding to each individual mutant in the 
pool.  We were able to assess the effects of heat shock on P. falciparum parasites in a high-
throughput manner.   
In comparing the individual heat shock screen to the pooled assay, we found that both 
techniques could produce a similar set of genes that were sensitive and resistant to febrile 
temperature.  Both assays agreed in identifying the extreme heat shock phenotypes.  This was 
evident when subjecting a group of individual mutants to heat shock three times as one of the 
mutants PB-115 or PF3D7_1227800 continued to have decreased growth and exhibit the 
sensitive heat shock phenotype.  The genes that were resistant to heat shock stress included a 
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PHISTa protein, var genes, an asparagine rich protein, and a repressor of RNA polymerase III 
transcription.  Those genes that had decreased growth or showed sensitivity to elevated 
temperatures were enzymes such as histone S-adenosyl methyltransferase, Acyl-CoA synthetase, 
RNA pseudouridylate synthase, protein phosphatase, a transcription factor with AP2 domains 
and a leucine rich repeat protein. Conserved genes of unknown function were present in both 
categories, however there was a consensus in genes that function in trafficking/signal 
transduction, export, transcription, and protein modification.  This discovery fits with the idea 
that the parasite must export or modify certain proteins to survive fever.  In the individual screen, 
many of these genes associate with heat shock proteins that help maintain homeostasis during 
stress or package proteins by folding or unfolding them in response to this condition.     
From this study, we identified proteins important in the heat shock response such as heat 
shock proteins, var genes, transport/export proteins, transcription factors, RNA binding proteins, 
protein kinases, surface proteins, and conserved proteins of unknown function.  The genes that 
appear to be more abundant after exposure to febrile temperature consist of those affiliated with 
nucleic acid metabolism and transcription regulation.  The microarray expression data from the 
Oakley 2011 study, revealed the upregulation and downregulation of many genes identified as 
biomarkers for malaria fever (14).  Our research looked at the functional protein level of some of 
these genes exhibiting the heat shock phenotype.  Many of the genes in our pooled screen that 
differed from that study included additional heat shock proteins, histone S-adenosyl 
methyltransferase, 40S and 60S ribosomal proteins, a duffy binding-like merozoite surface 
protein, a nucleoside transporter, and trafficking proteins to name a few.  This cadre of genes 
continues to suggest that post-translational modification is altered in the parasite, along with the 
remodeling of its membrane structure and transport mechanisms to provide protection during 
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elevated temperature.  Also, it is important to identify the insertion site of the piggyBac 
transposon, as the phenotype seen may be related to its insertion in the middle of a functional 
domain, as was the case with the var genes in the individual screen.  Additional experiments 
should be conducted to determine significance of the growth effect seen in these genes and if 
functional associations can be made. 
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Table 3.1: piggy Bac  Mutant List for Pooled Heat Shock Assay.  Red = Pool 1, Blue 
= Pool 2, and Green = Pool 3.  The mutants in these pools were combined into a master pool for 
heat shock.  
PB 
ID 
PlasmoDB ID Gene 
Start 
Gene 
End 
Insertion 
Site 
Gene  
Strand 
Gene Description 
1 PF3D7_0811300 567824 573148 568855 +  CCR4-associated factor 1 (CAF1) 
2 PF3D7_1305500 271411 273726 271629 + Mitogen-activated protein kinase 
phosphatase 1, putative (MKP1) 
3 PF3D7_0615900 662435 667855 667365 - Conserved Plasmodium protein, 
unknown function 
4 PF3D7_1122900 878969 895273 879695 + Dynein heavy chain, putative 
5 PF3D7_1141900 1676255 1677769 1676856 - Inner membrane complex protein 1b, 
putative (IMC1b) 
6 PF3D7_1475700 3117392 3118951 3116484 + Tubulin epsilon chain, putative 
7 PF3D7_0211100 451751 455116 451759 + Conserved Plasmodium protein, 
unknown function 
8 PF3D7_0203000 141625 147564 142289 - Conserved Plasmodium protein, 
unknown function 
9 PF3D7_0404600 247731 260147 250802 + Conserved Plasmodium membrane 
protein, unknown function 
10.1 PF3D7_0400100 28706 37677 34709 + Erythrocyte membrane protein 1, 
PfEMP1 (VAR) 
10.2 PF3D7_0627900 1119587 1120858 1119286 + Ribonuclease P protein subunit p29, 
putative (POP4) 
11 PF3D7_0416500 723073 724242 724234 - Repressor of RNA polymerase III 
transcription MAF1, putative 
12 PF3D7_1018300 729809 732856 733690 - Conserved Plasmodium protein, 
unknown function 
13 PF3D7_1360200 2406838 2408385 2406699 - Conserved protein, unknown function 
14 PF3D7_0511500 486602 516787 516248 + RNA pseudouridylate synthase, 
putative 
15 PF3D7_0611800 490858 501140 498591 - Conserved Plasmodium protein, 
unknown function 
16.1 PF3D7_0619900 840523 841224 841186 + Splicing factor 3A subunit 2, putative 
(SF3A2) 
16.2 PF3D7_0532000 1292410 1296199 1296386 + 28S ribosomal RNA 
17 PF3D7_0521900 888657 895144 889784 + Conserved Plasmodium protein, 
unknown function 
18 PF3D7_1219300 766654 774197 769606 - Erythrocyte membrane protein 1, 
PfEMP1 (VAR) 
19 PF3D7_1133700 1302173 1305987 1302725 + Conserved Plasmodium protein, 
unknown function 
20 PF3D7_0808700 440408 448062 446344 + Erythrocyte membrane protein 1, 
PfEMP1 (VAR) 
21 PF3D7_1136000 1403906 1414512 1404540 + Conserved Plasmodium protein, 
unknown function 
22 PF3D7_0931000 1248866 1251601 1250793 - Elongation factor Tu, putative 
23 PF3D7_0830900 1317600 1318341 1318070 - Plasmodium exported protein, 
unknown function 
24 PF3D7_1231800 1314696 1320170 1319997 + Asparagine-rich protein, putative 
25 PF3D7_1035800 1420533 1422671 1422622 + Probable protein, unknown function 
(M712) 
26 PF3D7_1444100 1801961 1825326 1812894 -  Conserved Plasmodium protein, 
unknown function 
28 PF3D7_1138900 1540804 1544163 1544148 + Unspecified product 
29 PF3D7_1441800 1702609 1703809 1703121 - Vacuolar-sorting protein SNF7, 
putative 
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Table 3.1: (Continued)   
PB 
ID 
PlasmoDB ID Gene 
Start 
Gene 
End 
Insertion 
Site 
Gene 
Strand 
Gene Description 
30 PF3D7_1345800 1831842 1834991 1833303 + Conserved Plasmodium protein, 
unknown function 
31 PF3D7_1432400 1275899 1282645 1281184 - Leucine-rich repeat protein (LRR5) 
32 PF3D7_0819800 891658 898502 896251 - Conserved Plasmodium protein, 
unknown function 
33 PF3D7_1207800 354540 357446 356310 - Conserved Plasmodium protein, 
unknown function 
34 PF3D7_1143500 1737256 1740029 1739772 - Conserved Plasmodium protein, 
unknown function 
35 PF3D7_1001700 92573 93526 92206 - Plasmodium exported protein 
(PHISTc), unknown function 
36 PF3D7_1019400 786503 787008 787283 + 60S ribosomal protein L30e, putative 
37 PF3D7_1311900 507900 509735 510072 + Vacuolar ATP synthase subunit a 
(vapA) 
38 PF3D7_1035700 1413200 1415293 1417438 + Duffy binding-like merozoite surface 
protein (DBLMSP) 
39 PF3D7_1103100 140048 140801 141915 - 60S acidic ribosomal protein P1, 
putative (RPP1) 
40 PF3D7_0815000 709333 710600 710781 - Selenoprotein (Sel3) 
42 PF3D7_1216100 646979 647860 648182 + Conserved Plasmodium membrane 
protein, unknown function 
43 PF3D7_0206100 245358 246699 246992 + Cysteine desulfuration protein SufE 
(SufE) 
45 PF3D7_1227000 1092160 1092651 1092023 - Conserved Plasmodium protein, 
unknown function 
48 PF3D7_1344000 1759466 1761991 1758853 + Aminomethyltransferase, putative 
49 PF3D7_1328700 1213394 1213615 1212674 + Plasmodium RNA of unknown function 
RUF1 
50 PF3D7_1138800 1533252 1539856 1532518 - Conserved Plasmodium protein, 
unknown function 
51 PF3D7_1327100 1138558 1141561 1138368 - Conserved Plasmodium protein, 
unknown function 
52 PF3D7_1136600 1441503 1445471 1445642 + Conserved Plasmodium protein, 
unknown function 
53.1 PF3D7_1200600 46788 56805 46222 - Erythrocyte membrane protein 1, 
PfEMP1 (VAR2CSA) 
53.2 PF3D7_0900800 52648 54020 52076 - Erythrocyte membrane protein 1 
(PfEMP1), exon 2, pseudogene (VAR) 
54 PF3D7_0902200 98175 100339 99320 - Serine/threonine protein kinase, FIKK 
family (FIKK9.3) 
55 PF3D7_0727200 1156748 1158409 1156274 - Cysteine desulfurase, putative (NFS) 
56 PF3D7_0105500 228485 229519 229890 - Conserved Plasmodium protein, 
unknown function 
57 PF3D7_1126200 1023790 1024496 1023203 - 40S ribosomal protein S18, putative 
58 PF3D7_1343700 1724817 1726997 1728031 - Kelch protein K13 (K13) 
59.1 PF3D7_1426400 1026262 1027144 1027315 - MORN repeat protein, putative 
59.2 PF3D7_0606000 250612 253803 253811 - Conserved Plasmodium protein, 
unknown function 
60 PF3D7_1330500 1284988 1287165 1284702 + Conserved Plasmodium protein, 
unknown function 
61 PF3D7_1342900 1682393 1693969 1694959 - Transcription factor with AP2 
domain(s) (ApiAP2) 
62 PF3D7_1302000 112792 113815 115505 - EMP1-trafficking protein (PTP6) 
63 PF3D7_0203600 166144 168051 168158 + Conserved Plasmodium protein, 
unknown function 
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Table 3.1: (Continued)   
PB 
ID 
PlasmoDB ID Gene 
Start 
Gene 
End 
Insertion 
Site 
Gene 
Strand 
Gene Description 
64 PF3D7_1108000 352556 354262 351780 + IWS1-like protein, putative 
65 PF3D7_0606000 250612 253803 253817 - Conserved Plasmodium protein, 
unknown function 
66 PF3D7_0614500 606142 607259 607866 - 60S ribosomal protein L19 (RPL19) 
67 PF3D7_0203700 168682 170136 170489 - Nucleolar preribosomal assembly 
protein, putative 
68 PF3D7_0601900 78190 78784 77404 + Conserved Plasmodium protein, 
unknown function 
69.1 PF3D7_0524400 1013453 1014550 1012936 - Cytosolic preribosomal GTP-binding 
protein, putative 
69.2 PF3D7_0612800 528060 529175 530075 - 6-cysteine protein (P12p) 
71 PF3D7_1001900 99379 100361 100751 - Plasmodium exported protein (hyp16), 
unknown function (PfJ23) 
72 PF3D7_1409500 370146 373006 373820 + Conserved Plasmodium protein, 
unknown function 
74 PF3D7_0402000 114601 116058 116369 - Plasmodium exported protein 
(PHISTa), unknown function 
76 PF3D7_1433400 1312304 1329577 1330867 - Conserved Plasmodium membrane 
protein, unknown function 
77 PF3D7_0322100 930640 932415 930071 - RNA triphosphatase (Prt1) 
78 PF3D7_0623900 977183 978049 979252 + Ribonuclease H2 subunit A, putative 
79.1 PF3D7_0103300 143640 146396 146981 - Conserved Plasmodium protein, 
unknown function 
79.2 PF3D7_1434200 1368815 1369796 1370157 - Calmodulin (CAM) 
80 PF3D7_1013600 533109 539825 532345 + Conserved Plasmodium protein, 
unknown function 
81 PF3D7_1350500 2015367 2018801 2020022 - Conserved Plasmodium protein, 
unknown function 
82 PF3D7_1206800 308214 310397 306444 + Conserved Plasmodium protein, 
unknown function 
83 PF3D7_1406900 251059 252826 249419 + Radical SAM protein, putative 
84 PF3D7_1221000 836912 843901 845511 - Histone-lysine N-methyltransferase, 
H3 lysine-4 specific (SET10) 
85 PF3D7_0916700 696863 698029 699679 - RNA-binding protein musashi, putative 
(HoMu) 
87 PF3D7_0812500 626069 628945 625232 - RNA-binding protein, putative 
91 PF3D7_1433900 1360002 1364558 1359496 + Protein kinase, putative 
92 PF3D7_0414600 658620 659538 659953 - Conserved protein, unknown function 
94 PF3D7_0110500 396591 403606 395817 + Bromodomain protein, putative 
95 PF3D7_0202100 109564 110580 109046 - Plasmodium exported protein 
(PHISTc), unknown function, liver 
stage associated protein 2 (LSAP2) 
96 PF3D7_1207300 343326 344361 342678 - Conserved Plasmodium protein, 
unknown function 
97 PF3D7_0405400 291251 300976 290343 + Pre-mRNA-processing-splicing factor 
8, putative (PRPF8) 
98 PF3D7_0807600 389596 394259 389064 - Conserved Plasmodium protein, 
unknown function 
99 PF3D7_1347200 1889853 1891121 1891837 - Nucleoside transporter 1 (NT1) 
100 PF3D7_1430000 1181664 1182982 1182677 - Conserved Plasmodium protein, 
unknown function 
101 PF3D7_0312400 524154 526439 527173 - Glycogen synthase kinase 3 (GSK3) 
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Table 3.1: (Continued)   
PB 
ID 
PlasmoDB ID Gene 
Start 
Gene 
End 
Insertion 
Site 
Gene 
Strand 
Gene Description 
102 PF3D7_1316000 668360 670745 672107 - Protein kinase, putative 
103 PF3D7_0604400 184892 185843 186830 + Conserved Plasmodium protein, 
unknown function 
104 PF3D7_0104200 182822 184222 186648 - StAR-related lipid transfer protein 
105 PF3D7_1333400 1370083 1370799 1369625 + Conserved protein, unknown function 
106 PF3D7_1139300 1556744 1565045 1567137 - Transcription factor with AP2 
domain(s) (ApiAP2) 
107 PF3D7_0505100 220839 229253 220076 + Trafficking protein particle complex 
subunit 8, putative (TRS85) 
108 PF3D7_1252300 2128400 2128786 2131213 - Conserved Plasmodium protein, 
unknown function 
109 PF3D7_1452500 2151823 2153614 2154633 - SNARE protein, putative (BET1) 
110 PF3D7_0937800 1495579 1503336 1507053 - Erythrocyte membrane protein 1, 
PfEMP1 (VAR) 
111 PF3D7_1004600 215717 219759 216125 + Conserved Plasmodium membrane 
protein, unknown function 
112 PF3D7_0731000 1333175 1334938 1336930 - Unspecified product, ncRNA 
114 PF3D7_0632800 1374797 1382627 1373882 - Erythrocyte membrane protein 1, 
PfEMP1 (VAR) 
115 PF3D7_1227800 1134370 1137648 1137689 - Histone S-adenosyl 
methyltransferase, putative 
116.
1 
PF3D7_1436200 1467629 1474438 1476670 - Conserved Plasmodium protein, 
unknown function 
116.
2 
PF3D7_0920300 831669 832648 831572 + Conserved Plasmodium protein, 
unknown function 
119 PF3D7_0630100 1254907 1256940 1257230 - Conserved Plasmodium protein, 
unknown function 
120 PF3D7_1459500 2436695 2439616 2436451 + Conserved Plasmodium protein, 
unknown function 
121 PF3D7_0523200 966123 969737 965601 + Conserved Plasmodium protein, 
unknown function 
122 PF3D7_0726000 1086570 1090357 1090517 + 28S ribosomal RNA 
123 PF3D7_1411100.
1 
447923 449968 450635 - Conserved Plasmodium membrane 
protein, unknown function 
124 PF3D7_0731600 1368161 1370596 1367266 + Acyl-CoA synthetase (ACS5) 
125 PF3D7_0622900 925105 931074 933481 - Transcription factor with AP2 
domain(s), putative (ApiAP2) 
126 PF3D7_1334800 1413102 1413947 1412492 - MSP7-like protein (MSRP2) 
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Figure 3.1:  Pooled Heat Shock Assay .  A. Flow diagram of assay method using multiple 
pools of piggyBac mutants. B. The equation used in calculation of fold change for QISeq 
analysis. 
 
 
  
Fold _ change = Percentageheat!shock (pb!muti )Percentagecontrol (pb!muti )
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Figure 3.2:  QISeq Library Construction.  Overview of the library generation process in 
which piggyBac gDNA is sheared, and independent libraries are sequenced using a specific 
Illumina protocol.  This image was adapted from figure 1 in Bronner et. al., “Manuscript in 
preparation” (4). 
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Figure 3.3: Heat Shock Results on Pooled Mutants .  A. Representations of parasite 
abundance as percentage within a pie chart.  B. QISeq analysis of pooled mutants showing fold 
change growth when comparing febrile temperatures to controls.   Fold changes of other 
replicates are ranked high to low according to the order of replicate 1.  
 
  71 
Figure 3.4: Heat Shock Co-expression Network of Pooled Mutants .  The mutants in 
this network are generated using the expression correlation with Pearson's R at larger than 0.80 
(as provided by Dr. Rays Jiang & Dr. Charley Wang at the University of South Florida). The 
thickness of the edges represents the level of expression correlations between two given genes.  
The heat shock winners (resistant, red circles) or losers (susceptible, blue circles) do not show a 
specific expression pattern, because they are in all major clusters.  Mutants with a large 
phenotype score or fold change are represented with larger circles.      
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Figure 3.5: Graph of GO Categories for Pooled Heat Shock Screen.  This bar graph 
represents the Gene Ontology or GO terms associated with some of the mutants detected in the 
large pool. 
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Figure 3.6: Pooled Screen Enrichment Map.  The image above categorizes the piggyBac 
mutants under heat shock by cellular compartment and various biological processes. GO terms 
were used to make this enrichment map. Red node size corresponds to the number of genes 
linked to that GO term.  The green edge size corresponds to the number of genes that overlap in 
GO terms.     
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CHAPTER FOUR:  
PHENOTYPIC CHARACTERIZATION OF THE PLA SMODIUM FA LCIPA RUM 
NOT1 MUTANT (PF3D7_1103800) 
 
Introduction 
The protozoan parasite Plasmodium falciparum, which is the most important causative 
agent of malaria, causes a debilitating disease responsible for a million deaths globally.  More 
than 124-283 million clinical cases are reported annually, of which most are young children (13).  
Falciparum malaria can lead to the severe clinical complications seen in patients from Africa and 
other endemic countries.  Once these parasites enter the body, they initially proceed to the liver, 
where they develop and proliferate before moving on to the red blood cells.  Pregnant women are 
disproportionately affected, but with preventative therapy and seasonal prophylaxis morbidity 
and mortality can be reduced.  However, widespread resistance to anti-malarial drugs is 
emerging as a major health threat, promoting the need for new drug discovery and development 
projects.  Core metabolic functions represent attractive new drug targets, since it is expected that 
these functions may be less likely to develop resistance mechanisms without deleterious effect 
on the parasite. 
Regulation of cell cycle development in the parasite is largely a response to their 
environment in which post-translational modifications occur at critical checkpoints during their 
48-hour life cycle.  According to the Central Dogma of Biology, gene expression flows from 
DNA to RNA to proteins and control of transcription and translation is vital to parasite survival.  
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Post-transcriptional control takes place in the nucleus, where RNA binds to proteins that form 
ribonucleoprotein particles and subsequently transports it to the cytoplasm for further processing 
(5).  Translational amplification or a high level of mRNA synthesis is also important to stability, 
since cell cycle defects may occur if there is dysregulation of mRNAs (5, 10).  Previous studies 
in the Adams lab using piggyBac insertional mutagenesis identified the carbon catabolite 
repressor protein 4 (CCR4) – associated factor 1 (ΔCAF1) is a critical regulator of expression for 
a subset of P. falciparum genes, especially genes expressed late in schizonts. The genome of the 
CAF1 clone was sequenced at Sanger, confirming its mutant phenotype was not due to SNPs, 
INDELs or other unrelated genomic mutations (4).  CAF1 is a component in the CCR4-NOT 
complex in which the major subunit is the Negative On TATA-less promoters protein (NOT1) 
and acts as a major scaffold holding each subunit together (Figure 4.1A).  By extending this 
discovery to another member of the CCR4-NOT complex, NOT1, we can begin to understand 
the role of such genes in mRNA metabolism and parasite development. 
The CCR4-NOT complex participates in various facets of mRNA synthesis, such as the 
activation and repression of mRNA initiation, mRNA elongation and degradation.  In addition to 
NOT1, there are four other NOT proteins in the CCR4-NOT complex that act as translational 
repressors in the model organism of yeast (6).  NOT family members block the attachment of 
TATA binding proteins to genes that lack the TATA promoter with the NOT2-NOT5 binding 
site in the C-terminal position and the CCR4-CAF1 binding site located at the N-terminus 
(Figure 4.1B, [1]). The other members of the complex function in ubiquitination and histone 
acetylation, important processes in the regulation of transcription.  Cells lacking NOT1 or CAF1 
have reduced mRNA degradation efficiency and collectively, all members may function as a type 
of chaperone complex (7).  In other organisms like Caenorhabditis elegans, NOT1 is important in 
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microtubule and spindle formation and CAF1 participates in somatic cell development (7).  In 
yeast, a knockout of NOT1 cannot be generated indicating that it is the only component of the 
CCR4-NOT complex essential for viability (12).  
Much about the function of NOT1 in Plasmodium is unknown, yet the NOT1 domain is a 
conserved motif.  Studies in P.berghei have shown that this protein complex is necessary for 
female gametocyte maturation as P bodies function in translational repression and mRNA 
stability (9).  In earlier studies with the ΔNOT1 clone, a 50% decrease in growth was observed 
compared to the wild-type control (unpublished data).  As seen with the effects of the ΔCAF1 
parasite, we hypothesize that the ΔNOT1 clone will also have a delay in invasion due to its slow 
growth phenotype.  This chapter is a basic study analyzing the ΔNOT1 mutant for distinct 
phenotypic changes observed in the ΔCAF1 parasite.    
 
Materials and Methods 
Plasmodium falciparum  Cell Culture 
The malaria parasite cultures were grown and maintained using standard methods from 
the MR4 manual.  Mutants of not1 and caf1 were previously made using the piggyBac 
transposon through transfection of P. falciparum NF54 with infected RBCs ‘preloaded’ with 
plasmid DNA (2, 3).  To ensure parasite invasion of only plasmid-loaded RBCs, mature blood-
stage parasites were purified on a MACS magnetic column (Miltenyi Biotec); 1 million purified 
parasites were added to erythrocytes loaded with 100 µg of the transposon plasmid and 50 mg of 
the transposase plasmid to start a 5 ml parasite culture.  Individual mutant clones were obtained 
by limiting dilution of parasites post-drug selection.   All clones were cultured at 37°C with 
mixed gas (5% O2, 5% CO2, and nitrogen) and 5% hematocrit (O+ blood from the Interstate 
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Blood Bank) in complete media.  The growth media contained RPMI 1640 from Invitrogen 
supplemented with 0.5% Albumax II (Invitrogen), 0.25% sodium bicarbonate, and 0.01 mg/mL 
gentamicin.  
 
Bioinformatics Analyses of piggy Bac  Mutants 
For comparative sequence analysis of NOT1, in silico data was gathered for 
PF3D7_1103800.  Initially, the deduced PF3D7_1103800 amino acid sequence was compared to 
the NOT1 sequences identified in Plasmodium spp., other Apicomplexa and eukaryotes.  
Sequence information was obtained from the NCBI BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and SMART databases (http://smart.embl-
heidelberg.de/).  Amino acid alignments were carried out in order to generate a multiple 
sequence alignment, using the Clustal W Multiple alignment editor, BioEdit, 
(http://jwbrown.mbio.ncsu.edu/BioEdit/bioedit.html) and MacVector® 10.5.1, as well as MEGA 
software version 5.01 (http://www.megasoftware.net/).  The aligned amino acid sequences were 
used to construct a neighbor-joining tree.  This method used 1000 replicates for the bootstrap 
values, which determined phylogenetic relatedness.  MEGA software was also employed to 
calculate evolutionary distance by the p-distance method along with constructing trees.  
 
Microarray Analysis 
Similar to the analysis of the PF3D7_0811300 CAF1 mutant, RNA extracts were 
collected from PF3D7_1103800 NOT1 mutant cultures at six time points (ER – early ring, LR – 
late ring, ET – early trophozoite, LT – late trophozoite, ES – early schizont, and LS – late 
schizont).  This allows us to examine the expression of the NOT1 mutant PF3D7_1103800 (E5) 
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and compare it with the CAF1 (F3) mutant and WT microarray expression data of the parent 
strain NF54.  The samples were analyzed in Dr. Julian Rayner’s lab at the Wellcome Trust 
Sanger Institute by Dr. Alena Pance, who statistically adjusted the RNA expression levels for 
evaluation of microarray data.  Log-transformed ratios of ΔNOT1, ΔCAF1, and WT values were 
provided with a cutoff greater than 1 denoting increased expression and <-1 denoting decreased 
expression (4).  
 
Western Blot Analysis 
Parasite cultures of NF54 WT and the NOT1 mutant were synchronized twice with 5% 
sorbitol (once at 0-8 hours post-invasion and again 8-12 hours later during the ring stage) at high 
parasitemia of at least 5-8%. The parasites were analyzed every 2 hours at mid-trophozoite stage 
until the late schizont stage or end of the cycle (32 hrs. – 48 hrs.).  To start, 120 mL cultures 
were used and at each timepoint, the parasites were magnetically purified through a MACS 
column.  The effluent was centrifuged, siphoned off leaving only the pellet, and washed once in 
1X PBS.  15% saponin in PBS (made fresh) was diluted to a final concentration of 0.15% and 
added to the pellet for a 10 minute incubation on ice in order to remove the red blood cell protein.  
The parasites were centrifuged at 2,000 x g for 5 minutes with removal of the supernatant and 
washed in ice-cold 1X PBS (3 times).  The pellet was resuspended in 1X PBS with protease 
inhibitor cocktail (Sigma) and centrifuged at 4°C for 5 minutes.  The supernatant was removed, 
and the pellet was resuspended in 2X SDS-PAGE sample buffer with boiling at 65°C for 5 
minutes.  The samples were stored at -80C until separation on a 4-12% NuPAGE precast gel 
(Invitrogen) and then transferred to a nitrocellulose membrane.  The primary antibody dilutions 
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for the erythrocyte binding antigen-175 (EBA-175) and the glideosome-associated protein 45 
(GAP45) were 1:1000 for both in order to probe the membrane.  
 
Immunofluorescence Assays 
The parasites are synchronized and purified at the schizont stage in preparation for the 
IFAs or immunofluorescence assays.  Infected parasites are counted using a hemocytometer and 
light microscope.  The magnetically purified schizonts were smeared on a glass slide, fixed 
overnight in 4% paraformaldehyde and 0.0075% glutaraldehyde in RPMI medium.  The slides 
were subsequently permeabilized in 1% Triton X-100 in PBS for 15 min., blocked in 3% BSA or 
bovine serum albumin for 1 hour at room temperature (RT).  A primary antibody dilution of 
1:100 was added to 3% BSA and incubation occurred at RT for 1 hour.  After multiple washes 
with PBS, the parasites were incubated with a 1:1000 dilution in PBS for 1 hour at RT.  With the 
addition of Hoechst (1:1000) for DNA staining and allophycocyanin (APC)-conjugated anti-
glycophorin A antibody (2 µg/mL) for red cell membrane staining, the parasites were incubated 
for 30 to 45 minutes in the dark at RT.  Antibodies to EBA-175, MSP-1, and GAP45 (generously 
provided by Dr. Julian Rayner’s group) were used in the experiment.  The parasites were washed 
in 1X PBS and suspended in mounting media (Fluormount G, Southern Biotech cat# 0100-01), 
covered and sealed for visualization. 
 
Live Video Microscopy 
Late stage schizonts were magnetically purified at high parasitemia, placed on a glass 
slide or a poly-L-lysine-coated Petri plate and viewed with a DeltaVision CORE microscope 
(Applied Precision).  The schizonts were doubly-labeled with Hoechst (10 µg /mL) 33342 and 
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allophycocyanin (APC)-conjugated anti-glycophorin A antibody (2 µg/mL) for 10 – 15 minutes 
at RT in the dark.  Afterwards, the parasites were washed in 1X PBS and covered for microscopy, 
where time-lapse video was taken.  
 
Results 
 Phylogenetic Analysis of the NOT1 Domain Shows Conservation among 
Plasmodium  
There are two genes in the P. falciparum genome coding for deduced NOT1 proteins with 
sequence homology to yeast and microarray data indicates both not1 genes are co-expressed in 
all stages (8, 11).  The amino acid sequence alignments reveal that the NOT1 domain is 
conserved among Plasmodium and other eukaryotes (Figure 4.2).  NOT1 has been analyzed 
phylogenetically and the neighbor-joining tree infers a not1 gene duplication event between both 
NOT1 proteins, PF3D7_1103800 NOT1a & PF3D7_1417200 NOT1b (Figure 4.3).  These data, 
together with the observation of a low sequence identity between Apicomplexa and other species 
support the hypothesis that NOT1 proteins have evolved to have distinct functions even though 
other subunits of the complex are single copy.  The attenuated growth resulting from the 
disruption of the PF3D7_1103800 NOT1a indicates that PF3D7_1417200 NOT1b cannot 
compensate for this loss of function, supporting the hypothesis that these scaffold proteins have 
at least some distinct functional roles required for the parasite’s intraerythrocytic growth and 
development. 
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Parasite Gene Expression is Affected in the not1  Mutant 
Changes in gene expression occur when not1 is disrupted with the piggyBac insertion 
(Figure 4.1B).  The expression profiles of the ΔNOT1 parasite, NF54 WT, and ΔCAF1 were 
compared during ring, trophozoite, and schizont stages.  There were minor differences shown in 
the heat map of the mutant parasite lines but major differences compared to the WT parent.  
There is also increased abundance at the ring stages of transcript for microneme proteins (EBA-
175) and surface proteins (MSP-1) for the mutants.  Motility proteins such as GAP45 have 
decreased expression in the ΔNOT1 compared to the wild-type in late schizont and early ring 
stages (Figure 4.4).  Immunoblot analysis of trophozoite to schizont stages demonstrated the 
early or mis-timed expression of invasion-related proteins (GAP45 and EBA-175) in the NOT1 
mutant (Figure 4.5).  These proteins are customarily expressed in the late schizont stage of WT 
parasites.  
 
Variation in Localization of Blood-Stage Proteins 
In the trophozoite and schizont stages for ΔNOT1, EBA-175 appears to present sooner in 
development and has a surface localization similar to Caf1 mutant cultures along the merozoites.  
Yet, EBA-175 is detected at the apical ends of merozoites in the NF54 WT strain (Figure 4.6).  
Typically, GAP45 is located around the membrane of schizonts or invading merozoites and is 
stained with a corresponding fluorophore.  GAP45 localizes to the parasite membrane in both the 
WT and ΔNOT1 schizonts.  MSP-1 also exhibits the same localization pattern between the 
mutant and wild-type, as it localizes around the merozoites or parasite nuclei. 
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NOT1 Mutant Parasites Show Similar Aberration in Egress to caf1  
Mutants 
The mutant and wild-type parasites were observed at the end of the blood stage by live 
video microscopy of magnetically purified schizonts.  Since the ΔNOT1 has a reduced fold 
change in growth compared to the NF54 WT, the phenotype of the mutant was expected to 
demonstrate a noticeable effect in late schizogony.  Images under differential interference 
contrast (DIC) microscopy reveal select schizont clusters (grape-like formation), which may 
result in a delayed burst or release of merozoites (Figure 4.7).  This was similar to the 
dysfunctional egress observed in previous studies with the CAF1 mutant, where schizont rupture 
was hindered (4).  
 
Discussion 
Forward genetic screens that utilize insertional mutagenesis techniques like the piggyBac 
system offer insight into the parasite’s genome and the function of potentially important genes.  
One of the genes in that mutant library is NOT1 and it has a role in mRNA degradation along 
with the deadenylase, CAF1.  Both genes are apart of the CCR4-NOT complex, which helps 
regulate gene expression in eukaryotes.  Control of gene expression is vital for parasite 
development and survival.  Previously, a CAF1 mutant was shown to have an aberrant egress 
function, delaying schizogony.  As the two genes are connected in the CCR4-NOT complex, a 
similar approach to characterization was used with NOT1 to determine its function.  
The Plasmodium falciparum NOT1 gene shows a constitutive expression pattern with 
possible variation in asexual stage expression.  The analysis of the genome revealed that two 
forms of NOT1 exist in Plasmodium species.  Other eukaryotes have one not1 gene and in yeast, 
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it is unable to be knocked out and remains essential for cell viability.  The second NOT1 may 
compensate for the other if disrupted, enabling the life cycle to continue unabated.  The gene 
itself appears to act as a bridge connecting the other members of the complex, taking on certain 
attributes of its neighbors due to the binding sites present in its structure.  Our results show that 
the ΔNOT1 has altered localization with EBA-175 and mis-timed expression of invasion related 
genes, similar to the ΔCAF1.  This type of characterization may identify checkpoints of 
vulnerability among the intraerythrocytic cycle in malaria.  The major discovery of this study is 
that the two NOT1 proteins of P. falciparum have distinct functional roles important for asexual 
intraerythrocytic growth and development.      
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Figure 4.1:  CCR4-NOT Complex .  A. This diagram shows the arrangement of CCR4-NOT 
proteins in malaria.  The NOT1 protein is the largest and is flanked by other members in the 
complex.  Image adapted from http://mpmp.huji.ac.il//maps/CCR4.html. B.  A schematic of not1 
disruption showing piggyBac repeats ITR1 and ITR2 flanking hdfr. 
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Figure 4.2:  NOT1 Domain Alignment.  The C-terminal portion of the NOT1 domain is 
aligned with the amino acid sequences of other proteins.  Conserved and similar residues are 
shaded in grey and black, respectively.      
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Figure 4.3:  Phylogenetic Analysis of the NOT1 Domain.  The neighbor-joining tree 
represents the phylogenetic analysis of sequences in the alignment of the full NOT1 domain.  
The scale bar represents 0.05 amino acid substitutions per site.  PF3D7_1103800 or NOT1 A is 
highlighted in red and PF3D7_1417200 (NOT1 B) is highlighted in blue.   
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Figure 4.4:  Gene Expression Heat Map.  The microarray analysis compares the 
expression levels of invasion and surface proteins in the NOT1 mutant and NF54 WT parasites.  
Increased expression is shown in yellow and decreased expression is blue.    
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Figure 4.5:  Expression of Invasion-related Proteins in the ΔNOT1  and WT.  The 
immunoblot analysis depicts protein expression of EBA-175 and GAP45 between the wild-type 
and mutant.    
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Figure 4.6:  Immunofluorescence of Parasite Proteins in WT and ΔNOT1 
cultures .  The IFA with MSP-1, EBA-175, and GAP45 antibodies reveals a localization pattern 
between mutant and WT cultures.  Nuclei are stained with Hoechst/DAPI (blue), EBA-175, 
MSP-1, and GAP45 (FITC, green), and the red blood cell membrane is stained red with anti-
glycophorin A. 
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Figure 4.7:  Snapshots from Live Video Microscopy depicting the NOT1 Mutant 
Phenotype .  These images display the delayed invasion or egress phenotype of the ΔNOT1 
parasite during the late schizont stage as egress is altered.  From Left to Right: Initial time point, 
15 minutes later, and 30 minutes after that.        
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CHAPTER FIVE:  
SUMMARY 
 
Conclusions 
Heat Shock Assay Development 
Fever is one of the hallmark symptoms of malaria and people living in endemic regions 
of the world must receive proper treatment if their diagnostic test or blood smear comes back 
positive.  Left unchecked, uncomplicated malaria can become complicated or severe, where the 
symptoms range from respiratory distress, acute anemia, organ failure to death.  A rise in body 
temperature during infection is the host’s way of defending itself.  This is a necessary immune 
function that inhibits the growth of malaria parasites.  The purpose of this study was to expand 
our current views on fever by identifying genes in the Plasmodium developmental cycle that 
could be either impervious or vulnerable to elevated temperatures.  Such a discovery would 
allow for the development of drugs targeting invasion and replication.  After all, it is the quick 
release of merozoites from the depleted red blood cell that initiate the fever response.   
The assay evolved from the concept that febrile episodes are cyclical and occur every 48 
hours, the length of the erythrocyte cycle in P. falciparum.  Zero to 24 hours post invasion is the 
typical duration of the ring stage and it is here that febrile temperature is applied to in vitro 
cultures of wild-type and mutant clones.  This increase in temperature effectively synchronizes 
the ring-stage parasites, while also preventing the further maturation of trophozoites and 
schizonts (4, 5).  The piggyBac mutant library provides us with a source of genetically altered 
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parasites whose function can be elucidated through advanced sequencing methods like QISeq or 
individual phenotype screens.  The heat shock occurred over 8 hours at 41°C until the parasite 
cultures were placed back at 37°C, akin to the fever breaking and near normal body temperatures 
being restored.   
For the first heat shock experiment in Chapter 2, one round of heat shock was used and 
mutants were assessed individually similar to the Oakley study (5) that served as a model for our 
experimental design.  In our study mutants were subjected to 8 hours of heat shock and allowed 
to recover at 37°C until the end of the cycle, 30 hours later.  At this stage, schizont populations 
were counted and growth rate compared.  Some parasites did proceed to the next cycle of rings, 
however that measurement may introduce another phenotype, delayed-death.  This exhibits a 
more pronounced growth inhibition in the next cycle and is usually a response to drug treatment.  
In the second experimental study using collections of pooled mutants, three rounds of heat shock 
took place every 48 hours over a period of 8 days, where growth between control and treated 
pooled samples was compared.  QISeq sequencing revealed that some parasites out-competed 
others and were more abundant in the pool after heat shock or were able to survive over other 
clones.  The mutants that were more successful in the pool functioned in transcription, protein 
modification, membrane/structural organization, and nucleic acid metabolism.   
In results with both types of the piggyBac mutants tested by heat, only a few showed a 
significant increase in growth compared to numerous mutations that increased sensitivity to fever. 
This result suggests that few factors are actually can enhance a parasite’s growth to fever while 
there are quite a few that help the parasite tolerate fever.  In terms of drug discovery of new 
targets the genes associated with mutant clones that were significantly decreased may represent 
suitable drug targets as they function to protect parasites from febrile temperatures.  Many of 
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these genes were affiliated with pathways of RNA degradation, pathogenesis or invasion, the 
spliceosome, endocytosis, and fatty acid metabolism.  Furthermore, mutants of consideration for 
drug discovery would be those whose growth affect is only due to heat shock.  The attenuation 
category was provided for these mutants as part of an earlier growth screen at 37°C (2).  If they 
were originally non-attenuated at 37°C and subsequently attenuated either positively or 
negatively after heat shock, they could prove important in affecting the growth and development 
of P. falciparum parasites.  
 
Partial Characterization of the NOT1 mutant 
The phenotypic characterization of the NOT1 mutant was the continuation of work 
previously conducted on the CAF1 knockout.  NOT1 and CAF1 are both members of the CCR4-
NOT complex, which is responsible for mRNA degradation and translational repression.  Like 
most protein complexes, it is multi-faceted and functions in many ways.  Our goal was to 
determine the function of NOT1 in P. falciparum.  Sequence alignment revealed a conserved 
NOT1 domain and similarity to other Plasmodium species.  Additionally, there are two NOT1s 
present in the malaria parasite and they seem to be expressed together.  Not all of the members of 
the complex have duplicate status, so a functionally distinct CCR4-NOT complex may not exist.  
However, determining the role of the larger not1 gene (NOT1 B) may be the subject of a follow-
up study if a gene knockout could be made with NOT1 A or PF3D7_1103800.  All together, 
NOT1 acts as a scaffold and exhibits some gene expression and localization behavior similar to 
CAF1 when the gene is disrupted, causing delayed egress (3). 
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Future Studies 
The host-parasite relationship is complex and involves many factors, some environmental 
and others genetic.  While the race to find the answer for anti-malarial drug resistance continues, 
researchers must look at every avenue of human and parasite biology.  In the genetics defense 
realm, sickle cell and other blood disorders confer protection against malaria.  Sickle-cell 
heterozygotes or patients that have sickle-cell trait (one abnormal hemoglobin gene) have a 
better chance of survival during seasons of P. falciparum malaria transmission [1].   This level of 
innate resistance along with the other hemoglobinopathies offers some relief from the parasite 
load as does the human fever response.  More mutants in the piggyBac library will need to be 
screened for the heat shock phenotype and possibly complemented to test the rescue of growth 
similar to the wild-type.  The generation of possible drug targets is ideal for combating malaria 
as chemical compounds will need to be tested for efficacy through a drug screen.       
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